Method of treating an intraosseous nerve

This invention relates to a method of straddling an intraosseous nerve with an energy transmitting device to improve the therapeutic treatment of the nerve.

Skip to: Description  ·  Claims  ·  References Cited  · Patent History  ·  Patent History
Description
RELATED APPLICATIONS

This application is a divisional reissue application of U.S. patent application Ser. No. 13/541,591, filed on Jul. 3, 2012, which is an application for reissue of U.S. Pat. No. 7,749,218, which issued Jul. 6, 2010 from U.S. patent application Ser. No. 11/123,766, which is a divisional of U.S. patent application Ser. No. 10/260,879, filed Sep. 30, 2002, entitled “Method of straddling an intraosseous nerve”, now issued as U.S. Pat. No. 6,907,884, the specification of which is incorporated by reference.

Notice: More than one reissue application has been filed for the reissue of U.S. Pat. No. 7,749,218. The reissue applications include the present divisional reissue application and U.S. application Ser. No. 13/541,591, filed on Jul. 3, 2012, which is a reissue application of U.S. Pat. No. 7,749,218.

BACKGROUND OF THE INVENTION

In an effort to reduce back pain through early intervention techniques, some investigators have focused upon nerves contained within the vertebral bodies which are adjacent the problematic disc.

For example, PCT Patent Publication No. WO 01/0157655 (“Heggeness”) discloses ablating nerves contained within the vertebral body by first boring into the vertebral body with a nerve ablation device, placing the tip of the device in close proximity to the nerve, and then ablating the nerves with the tip. Heggeness discloses using laser devices, electricity transmitting devices, fluid transmitting devices and thermal devices, and devices for carrying either chemotherapeutic or radioactive substances as candidate nerve ablation devices.

In describing techniques using electricity transmitting devices, Heggeness discloses “raising the temperature of tip 24 such that the intraosseous nerve is ablated by the heat generated by electrical current passing through tip.” See Heggeness at 8,28.

Heggeness further discloses multiple methods of accessing the intraosseous nerve (ION). However, each of these methods essentially disclose either i) boring a straight channel into the vertebra such that placement of an electrode tip near the end of that channel will bring the electrode tip sufficiently close to the ION to effect its ablation, or ii) accessing the basivertebral nerve (BVN) via the vertebral foramen. None of these techniques recognize how to effectively carry out nerve ablation when the precise locations of the ION is unknown, or when the electrode tip can not be maneuvered relatively close to the ION.

EPO Patent Published Patent Application No. EP 1 059067 A1 (“Cosman”) discloses ablative treatment of metastatic bone tumors, including those within the spine. Pain relief is reportedly achieved by penetrating the bone wall with a suitable probe, and applying heat through the probe to ablate either the bone tumor or the tissue near the bone tumor. Cosman teaches the use of both monopolar and bipolar probes in this application. Cosman also teaches that the treatment may also be used to ablate the nerves and nerve ramifications in and/or around the bone to desensitize them against further tumor encroachment. See Cosman at col. 11, lines 7-11.

However, monopolar approaches require the use of a grounding pad beneath the patient and allows energy to flow from the probe and to dissipate in the surrounding tissue. Because the path by which the energy flows from a monopolar probe to its corresponding pad is uncontrolled, the energy may undesirably flow through sensitive tissue, such as the spinal cord. Since this method may cause undesired local muscle or nerve stimulation, it may be difficult or dangerous to operate in sensitive areas of the human body.

Cosman discloses devices whose electrodes can deviate from the axis of the access channel. In particular, Cosman discloses steerable tips, spring-like electrodes that take a straight shape within the catheter and then curve upon exiting the catheter. Cosman discloses that the curved portion of the electrode may be a rigid and rugged permanent curve, or it may be a flexible configuration so that it can be steered, pushed or guided by the clinician to be positioned at various location. See Cosman at col. 8, lines 40-50). Cosman discloses that electrodes may comprise tubing made of elastic or super-elastic metal such as a spring steel or nitonol tubing so that the electrode can be inserted into straight segments of the cannula and still describes a curved path when the curved portion emerges from the opening. See Cosman at col. 10, lines 11-16. Cosman also discloses an electrode having a flexible but steerable tip which can define an arc, as set by the physician. See Cosman at col. 14, line 3.

In sum, Heggeness and Cosman disclose methods of treating that assume the tip of the electrode can be directed substantially to the target tissue.

A few investigators have examined the effectiveness of heating bone with monopolar RF electrodes. DuPuy, AJR: 175, November 2000, 1263-1266 noted decreased heat transmission at a 10 mm distance from the electrode through cancellous bone in ex vivo studies. DuPuy notes that local heat sinks from the rich epidural venous plexus and cerebrospinal fluid pulsations may account for the decreased heat transmission in cancellous bone. Tillotson, Investigative Radiology, 24:11, November 1989, 888-892, studied the percutaneous ablation of the trigeminal ganglion using RF energy, and found that bone marrow necrosis was limited to a sphere of about 1 cm in diameter, regardless of the probe size and duration of heating. Tillotson further reports that Lindskog showed that the transmission of heat within bone is sharply limited by blood flow, and that lethal temperatures cannot be sustained over great distances.

In sum, these investigators appear to report that the well-vascularized nature of bone appears to limit the heating effect of RF electrodes to a distance of less than about 0.5 cm from the tip.

U.S. Pat. No. 6,312,426 (“Goldberg”) discloses a system of RF plate-like electrodes for effecting large, uniform, and extended ablation of the tissue proximate the plate-like electrodes. In some embodiments, the plate-like electrodes are placed on the surface of the body tissue, where the ablation is desired, and are configured to lie approximately parallel or opposing one another, such that they make a lesion by coagulating most of the body tissue volume between them. Goldberg appears to be primarily directed to the treatment of tumors. Goldberg states that one advantage of the system is that the surgeon need not determine the precise position of the tumor. See Goldberg at col. 3, line 59-60. Goldberg does not appear to specifically discuss the treatment of nerves.

U.S. Pat. No. 6,139,545 (“Utley”) discloses a facial nerve ablation system including at least two spaced apart bi-polar probe electrodes spanning between them a percutaneous tissue region containing a facial nerve branch. Utley teaches that the size and spacing of the electrodes are purposely set to penetrate the skin to a depth sufficient to span a targeted nerve or nerve within a defined region. See col. 5, lines 44-47. Utley further teaches that the system makes possible the non-invasive selection of discrete motor nerve branches, which are small and interspersed in muscle, making them difficult to see and detect, for the purpose of specifically targeting them for ablation. See col. 2, lines 20-24. Utley does not disclose the use of such a system for the treatment of IONS, nor rigid probes, or deployable electrodes. The probes of Utley

SUMMARY OF THE INVENTION

In attempting to place an electrode in close proximity to the BVN, the present inventors have found the approaches disclosed in the teachings of the art to be somewhat problematic. In particular, although the location of the BVN is somewhat well known, the BVN is radiolucent and so its precise location cannot be easily identified by an X-ray. Since the BVN is also extremely thin, knowingly placing the electrode in close proximity to the BVN may be problematic. Moreover, since conventional RF electrodes appear to heat only a fairly limited volume of bone, misplacement of the electrode tip vis-à-vis the BVN may result in heating a volume of bone that does not contain the BVN.

For example, and now referring to FIGS. 1 and 2, there is provided a representation of a treatment scheme involving the placement of a conventional bipolar electrode device in close proximity to the ION. In these FIGS., the ION is represented by the solid line identified as ION, while the vertically-disposed dotted lines identify the edges of the zone within which the practitioner believes the ION likely resides (i.e., the ION residence zone, or “IRZ”). As shown in FIGS. 1 and 2, if the ION is substantially in the center of the ION residence zone, then placement of the bipolar electrode either on the left hand boundary of the ION residence zone (as in FIG. 1) or substantially in the middle of the ION residence zone (as in FIG. 2) satisfactorily locates the electrodes in a region that allows the current flowing from the electrodes to flow across the ION. Since the current flowing across the ION may resistively and conductive heat the local bone tissue and the ION will be heated to therapeutically beneficial temperatures, these scenarios may provide beneficial treatment of the ION.

However, and now referring to FIG. 3, if the ION is substantially at the right edge of the ION residence zone, then placement of the bipolar electrodes on the left hand side of the ION residence zone fails to locate the electrodes in a region that allows the current flowing from the electrodes to flow across the ION. Accordingly, current flowing across the electrodes can not resistively heat the ION. Moreover, since bone is a heat sink that effectively limits the heat transport to about 0.5 cm, the heat produced by the electrodes may be effectively dissipated before it can reach the ION by conduction.

Similarly, and now referring to FIG. 4, if the ION is substantially at the left edge of the ION residence zone, then placement of the bipolar electrodes in the middle of the ION residence zone fails to locate the electrodes in a region that allows the current flowing from the electrodes to flow across the ION. Again current flowing across the electrodes can not resistively heat the ION, and the heat sink quality of bone may effectively dissipate the heat produced by the electrodes before it can reach the ION by conduction.

Moreover, even if the precise location of the BVN were known, it has been found to be difficult to access the posterior portion of the BVN from a transpedicular approach with a substantially straight probe.

Therefore, the present inventors set out to produce a system that allows the practitioner to heat the BVN without having to know the precise location of the BVN, and without having to precisely place the electrode tip next to the portion of the BVN to be treated.

The present invention relates to the production of a large but well-controlled heating zone within bone tissue to therapeutically treat an ION within the heating zone.

Now referring to FIGS. 5-6, there is provided a representation of an embodiment of the present invention in which electrodes E1 and E2 respectively disposed probes (not shown) therapeutically treat the ION. FIG. 5 provides a schematic representation of the electric field EF produced in the bone tissue by activation of the electrodes. In this case, the electric field is relatively thin. FIG. 6 provides a schematic representation of the total heating zone THZ produced by the electric field of FIG. 5 including both an inner resistive heating zone IR (represented by open circle) and an outer conductive heating zone OC (represented by closed circles). In this case, the inner resistive zone is produced by the joule heating of bone tissue disposed within the electric field EF, while the outer conductive zone is heated by conduction of heat from the resistive heating zone.

Still referring to FIG. 6, the present inventors have found that positioning the active and return electrodes of an energy-transmitting device in a manner that allows the electrodes to straddle the ION residence zone IRZ provides a large but well-controlled total heating zone (IR+OC) within bone tissue to therapeutically treat the ION within the heating zone. Since the total heating zone is large and the electrodes straddle the IRZ, there is a high level of confidence that a portion of the ION will be present within the total heating zone. Since the total heating zone is well controlled, there is no danger (as with monopolar systems) that current flowing from the active electrode will undesirably affect collateral tissue structures

Now referring to FIG. 7, if the ION is in fact substantially in the center of the ION residence zone, then placement of the bipolar electrodes in a manner that straddles the ION residence zone allows the production a total heating zone between the electrodes that includes a portion of the ION therein.

Moreover, the present invention allows the practitioner to therapeutically treat the ION even when the ION is in fact located at the edges of the ION residence zone IRZ. Now referring to FIGS. 8 and 9, if the ION is located substantially at the right edge (as in FIG. 8) or the left edge (as in FIG. 9) of the ION residence zone IRZ, then placement of the bipolar electrodes in a manner that straddles the ION residence zone still allows the production a total heating zone between the electrodes that includes a portion of the actual ION therein.

Therefore, the straddling of the ION residence zone by the present invention satisfactorily locates the electrodes so that the total heating zone produced by the electrode activation includes the ION irrespective of the actual location of the ION within the ION residence zone IRZ, thereby guaranteeing that the electrodes will always heat the ION to therapeutically beneficial temperatures.

Therefore, in accordance with the present invention, there is provided a method of therapeutically treating a bone having an intraosseous nerve ION defining first and second sides of the bone, comprising the steps of:

  • a) inserting an energy device having an active and a return electrode into the bone,
  • b) placing the active electrode on the first side of the bone and the return electrode on the second side of the bone to define a total heating zone therebetween, and
    applying a sufficiently high frequency voltage between the active and return electrodes to generate a current therebetween to resistively beat the total heating zone sufficient to denervate the ION.

In addition, the present invention provides a very controlled total heating zone which exists substantially only between the paired electrodes. The ability of the present invention to both therapeutically heat the BVN with substantial certainty and to minimize the volume of bone tissue affected by the heating appears to be novel in light of the conventional bone-related technology.

Accordingly, the present invention is further advantageous because it allows the clinician to create a sufficiently large heating zone for therapeutically treating the ION without requiring direct access to the ION.

Thus, in preferred embodiments, the present invention is advantageous because:

  • 1) it does not require knowing the precise location of the ION,
  • 2) it does not require directly accessing the ION, and
  • 3) its controlled heating profile allows the clinician to avoid heating adjacent structures such as the healthy adjacent cancellous bone tissue, the spinal cord or opposing vertebral endplates.

Accordingly, there is also provide a method of therapeutically treating a vertebral body having a BVN defining first and second sides of the vertebral body, comprising the steps of:

  • a) determining a BVN residence zone within which the BVN likely resides, the BVN residence zone having a first side and a second side,
  • b) inserting an energy device having an active and a return electrode into the vertebral body,
  • c) placing the active electrode on the first side of the residence zone and the return electrode on the second side of the residence zone to define a total heating zone therebetween, and
  • d) applying a sufficiently high frequency voltage between the active and return electrodes to generate a current therebetween to resistively heat the total heating zone to a temperature sufficient to denervate the BVN.

DESCRIPTION OF THE FIGURES

FIGS. 1 and 2 depict the treatment of the BVN with a conventional bipolar electrode.

FIGS. 3 and 4 depict the difficulty of treating a BVN with a conventional bipolar electrode.

FIGS. 5 respectively depict top views of an electric field and a total heating zone produced within bone tissue by an embodiment of the present invention.

FIGS. 7-9 depict the treatment of the BVN with a bipolar electrode apparatus of the present invention.

FIGS. 10a and 10b disclose anterior and upper cross-sectional views of a straddled ION that extends in a plane above the electrodes but within the total heating zone.

FIG. 11 is a cross-sectional anterior view of an embodiment of the present invention in which the total heating zone has dumb-bell type resistive heating zones.

FIG. 12 depicts a top view of the treatment of the BVN with a bipolar electrode apparatus of the present invention wherein the distal ends of the probes are located substantially at the midline of the vertebral body.

FIG. 13 discloses cross-sections of components of a preferred dual probe apparatus according to the present invention.

FIG. 14 discloses an embodiment of the present invention in which a portion of the probe shaft acts as an electrode.

FIGS. 15-18 discloses four embodiments of the present invention in which at least a portion of the electrode faces thereof are disposed in a substantially parallel relation.

FIG. 19 discloses a cross-sectional view of an apparatus of the present invention in which the cannula has a bore having a distal bend and a lateral opening.

FIGS. 20a and 20b disclose cross-sectional views of an apparatus of the present invention in which the cannula has a proximal bend.

FIGS. 21a and 21b disclose cross-sectional views of an apparatus of the present invention in which the probe has a pivoted portion containing an electrode.

FIG. 22 discloses a probe of the present invention having reverse conical electrodes.

FIG. 23 discloses a probe of the present invention having a plurality of active electrodes and a corresponding plurality of return electrodes.

FIG. 24 discloses a bipolar probe of the present invention in which the return electrode has a relatively large surface area.

FIG. 25 presents a cross-sectional view of an articulated probe of the present invention having both active and return electrodes.

FIG. 26 discloses the treatment of a posterior portion of the BVN with a bipolar electrode apparatus of the present invention. FIGS. 27a-d disclose respective top, anterior, lateral and perspective views of the placement of a bipolar electrode apparatus of the present invention within a vertebral body.

FIGS. 28a and 28b show the location of thermocouples T0-T14 within the vertebral body.

FIG. 29a-c present the temperatures recorded by thermocouples T0-T14.

FIG. 30a-b present the peak temperatures recorded by thermocouples T0-T14 within the vertebral body.

FIGS. 31a-e present top views of a preferred use of the articulated probe of FIG. 25.

FIG. 32 presents a dual articulated needle embodiment of the present invention.

 DETAILED DESCRIPTION OF THE INVENTION

For the purposes of the present invention, the “resistive heating zone” is the zone of bone tissue that is resistively heated due to an energy loss incurred by current travelling directly through the bone tissue. Resistive heating, “joule” heating and “near-field” heating may be used interchangeably herein. The “conductive heating zone” is the zone of bone tissue that is heated due to the conduction of heat from an adjacent resistive heating zone. The total heating zone THZ in a bone tissue includes both the resistive heating zone and the conductive heating zone. The border between the conductive and resistive heating zones is defined by the locations where the strength of the electric field is 10% of the maximum strength of the electric field between the electrodes. For the purposes of the present invention, the heating zones encompass the volume of bone tissue heated to at least 42° C. by the present invention. For the purposes of the present invention, the “first and second sides” of a vertebral body are the lateral-lateral sides intersected by the BVN.

The therapeutic treatment of the ION may be carried out in accordance with the present invention by resistive heating, conductive heating, or by hybrid heating.

In some embodiments, the therapeutic heating of the ION is provided by both resistive and conductive heating. In some embodiments thereof, as in FIG. 6, the electrodes are placed such that the ION passes through resistive heating zone IR, so that length L1 of the ION is therapeutically heated by bone tissue in the resistive heating zone IR and lengths L2 and L3 of the ION are therapeutically heated by the bone tissue in the conductive heating zone OC.

In embodiments wherein the therapeutic heating of the ION is provided substantially by both resistive and conductive heating, it is preferred that the length L1 of the ION treated by resistive heating comprise at least 25% of the total therapeutically treated length of ION, more preferably at least 50%. In many embodiments, the peak temperature in the resistive heating zone IR is between 40° C. and 60° C. greater than the peak temperature in the conductive heating zone OC. Preferably, the peak temperature in the resistive heating zone IR is no more than 15° C. greater than the peak temperature in the conductive heating zone OC, more preferably no more than 10° C., more preferably no more than 5 degrees.

Now referring to FIGS. 10a and 10b, in some embodiments, the therapeutic heating of the ION is provided essentially by the conductive heating zone OC. This may occur when the ION is in fact located substantially far from the middle of the ION residence zone IRZ. In such an instance, the electrodes are placed such that the ION passes only through the conductive heating zone, so that length L2 of the ION is therapeutically heated by bone tissue in the conductive heating zone OC.

In preferred embodiments thereof, it is desired that the separation distance SD between the ION and the resistive heating zone IR be no more than 1 cm. This is desired because the closer the ION is to the resistive heating zone, the higher the temperature experienced by the ION length L2. More preferably, the separation distance is no more than 0.5 cm, more preferably no more than 0.2 cm.

In some embodiments, as in FIG. 10, the electric field is sufficiently strong to be located substantially continuously between the two electrodes. This typically occurs when the electrodes are very close together (i.e., no more than 5 mm apart). In others, however, as in FIG. 11, the electric field is relatively weak and so resides substantially only in the vicinity of the two electrodes. In such cases, and now referring to FIG. 11, inward energy flow from the resistive heating zones IR conductively heats the intermediate area of the conductive heating zone OC1. Preferably, the peak temperature in the resistive heating zone IR is no more than 15° C. greater than the peak temperature in the intermediate conductive heating zone OC1, more preferably no more than 10° C., more preferably no more than 5° C.

In preferred embodiments, the present invention is carried out via a dual probe system. In particular, the present invention preferably comprises an energy delivery device comprising a first probe having an active electrode and a second probe having a return electrode. Now referring to FIG. 12, this dual probe embodiment allows the surgeon to approach the BVN from separate sides of the vertebral body to easily straddle the IRZ with the electrodes. With such a device, the surgeon can place the first probe 601 having an active electrode 603 on a first side of the vertebral body and the second probe 611 having a return electrode 613 on a second side of the vertebral body, and then align the paired electrodes so that their activation produces a total heating zone that straddles the IRZ and therefore the BVN therein.

Since aligning the electrodes of such an apparatus to straddle the ION merely requires advancing the probes into the vertebral body, no complicated navigation is required. The present inventors have appreciated that, even if the location of the BVN were precisely known, conventional methods of accessing the BVN require either i) the BVN to be naturally located within the vertebral body so as to intersect the axis of the pedicle (Heggeness), or require a complicated probe configuration or navigation (such as those described by Cosman). Because the dual probe approach simply requires substantially linear advance of a pair of substantially straight probes, it is much simpler and/or much more robust than the conventional methods of accessing nerves in bone. Indeed, with this embodiment of the present invention, the clinician may now desirably access the vertebral body through the pedicles with substantially straight probes and have a high confidence that their activation can therapeutically treat the BVN.

Therefore, in accordance with the present invention, there is provided a method of therapeutically treating a vertebral body having a BVN, comprising the steps of:

  • a) providing an energy device having an active electrode having a first face and a return electrode having a second face into the vertebral body, and
  • b) placing the active electrode in the vertebral body to face a first direction,
  • c) placing the return electrode in the vertebral body to face a second direction, the first and second faces defining an angle 2δ of no more than 60 degrees, and
    applying a sufficiently high frequency voltage difference between the active and return electrodes to generate a current therebetween to produce a total heating zone to therapeutically heat the BVN.

Therefore, in accordance with the present invention, there is provided a method of therapeutically treating a vertebral body having a BVN, comprising the steps of:

  • a) providing an energy device having an active electrode and a return electrode,
  • b) placing the active and return electrodes in the vertebral body to define an electrode axis, the axis forming an angle β of between 50 and 90 degrees with the BVN, and
  • c) applying a sufficiently high frequency voltage difference between the active and return electrodes to generate a current therebetween to produce a total heating zone to therapeutically heat the BVN.

Now referring to FIG. 13, there is provided a preferred dual probe apparatus according to the present invention comprising first 101 and second 151 cannulae, first 201 and second 251 stylets, first 301 and second 351 probes, and a power supply 401 in electrical connection with the probes. For simplicity, only a single cannula, stylet and probe will be further described. However, the skilled artisan will appreciate that preferred embodiments use two sets of such devices.

Now referring to FIG. 13, cannula 101 comprises a shaft 103 having a longitudinal bore 105 therethrough defining an inner diameter DC. Distal opening 109 of the cannula provides a working portal for the probe. It is further sized to allow the distal end of the probe to advance past the distal end 107 of the cannula. The length Lc of the cannula is sized to reach from the patient's skin to a location within the cancellous bone region of the target bone. Preferably, the cannula is made of a material selected from the group consisting of metal and polymer, and is preferably polymer. In many embodiments, the cannula is made of an insulating material in order to prevent stray current from the probe from contacting non-targeted tissue.

In some embodiments, the cannula is shaped so as to guide the probe towards the midline of the vertebral body. This inward guidance will help move the electrodes closer to the BVN. In some embodiments, at least a portion of the cannula bore is curved. In some embodiments, at least half of the length of the cannula bore is curved. In other embodiments, substantially only the distal end portion of the cannula bore is curved.

Stylet 201 comprises a shaft 203 having a longitudinal axis A and a proximal 205 and distal end 207. Disposed at the distal end of the shaft is a tip 209 adapted for boring or drilling through cortical bone. The outer diameter DO of the stylet shaft is preferably adapted to be received within the inner diameter DC of the cannula.

For the purposes of the present invention, the combination of the cannula and the stylet is referred to as a “cannulated needle”. In some embodiments, access to the vertebral body is gained by first placing the stylet in the cannula to produce a cannulated needle, piercing the skin with the cannulated needle, and advancing the cannulated needle so that the stylet tip reaches a target tissue region within the cancellous portion of the vertebral body, and then withdrawing the stylet. At this point, the cannula is conveniently located at the target tissue region to receive a probe of the present invention.

Probe 301 comprises a shaft 303 having a longitudinal axis B, a distal end portion 305 and a proximal end portion 307. Disposed near the distal end portion of the probe is first electrode 309 having a first face 331 and a connection face 333. The probe is designed so that the connection face of the first electrode is placed in electrical connection with a first lead 403 of the power supply. In this particular embodiment, the shaft has a longitudinal bore 311 extending from the proximal end portion up to at least the first electrode. Disposed within the bore is a wire 321 electrically connected at its first end 323 to the first electrode and having a second end 325 adapted to be electrically connected to a first lead of a power supply.

Therefore, in accordance with the present invention, there is provided an intraosseous nerve denervation system, comprising:

  • a) a cannula having a longitudinal bore,
  • b) a stylet having an outer diameter adapted to be received within the longitudinal bore and a distal tip adapted to penetrate cortical bone, and
  • c) a first probe comprising:
    • i) an outer diameter adapted to be received within the longitudinal bore, and
    • ii) a first electrode, and
    • iii) a lead in electrical connection with the first electrode.

In some embodiments, the outer surface of the probe is provided with depth markings so that the clinician can understand the extent to which it has penetrated the vertebral body.

In some embodiments in which a cannulated stylet is first inserted, the stylet is removed and the cannula remains in place with its distal opening residing in the target tissue while the probe is inserted into the cannula. In this embodiment, the cannula provides a secure portal for the probe, thereby insuring that the probe can enter the bone safely. This embodiment is especially preferred when the probe is made of a flexible material, or is shaped with an irregular cross-section that could undesirably catch on the bone during probe advancement into the bone.

In the FIG. 13 probe disclosed above, probe 301 has a blunt tip. In other embodiments, however, the probe carrying an electrode can be configured to possess a sharp distal tip having sufficient sharpness to penetrate cortical bone. With such a tip, the clinician can eliminate steps in the procedure that are related to either the stylet or the cannulated stylet, and thereby save time.

Now referring to FIG. 14, in some embodiments, the electrode may include a portion of the probe shaft. For example, in the case of probe 1401, the probe comprises:

a) an inner electrically conductive shaft 1403 in electrical connection with a power supply 1409, and

b) an outer insulating jacket 1405 wrapped around a portion of the shaft.

In this configuration. the placement of the jacket provides a distal uninsulated shaft portion 1407 that could be used as an electrode. Preferably, the distal uninsulated portion of the shaft has a length of between 3 mm and 8 mm, and is more preferably about 5 mm. In preferred embodiments thereof, the insulation is selected from the group consisting of polyimide tape, PTFE tape, and heat shrink tubing. Preferred thickness of the insulation range from about 0.00025 to 0.0005 inches.

In other embodiments using insulating jackets, the jacket has either a longitudinally extending slit or slot that exposes a longitudinal surface area of the underlying shaft, thereby producing either an essentially linear or an essentially planar electrode. In such embodiments, the distal end of the shaft may preferably be insulated. In other embodiments using insulating jackets, the insulated portion may comprises a proximal jacket and a distal jacket positioned to provide a space therebetween that exposes a surface area of the underlying shaft to produce the electrode. In some embodiments, the proximal and distal jacket substantially encircle the shaft to provide an annular electrode therebetween.

In some embodiments in which a cannulated stylet is used, both the stylet and the cannula are removed, and the probe is inserted into the hole created by the cannulated stylet. In this embodiment, the hole provides a large portal for the probe. This embodiment conserves the annulus of bone removed by the cannula, and so is preferred when the probe has a relatively large diameter (e.g., more than 8 mm in diameter).

In some embodiments in which a cannulated stylet is used, the cannula comprises at least one electrode In this embodiment, the cannula acts as the probe as well. With this embodiment, the clinician can eliminate steps in the procedure that are related to introducing a body into the cannula. In some embodiments, the outer surface of the cannula is provided with depth markings so that the clinician can understand the extent to which the cannula has penetrated the vertebral body.

In some embodiments in which a cannulated stylet is first inserted, the stylet comprises at least one electrode. In this embodiment, the stylet acts as the probe as well. With this embodiment, the clinician can eliminate steps in the procedure that are related to removing the stylet and introducing a body into the cannula. In some embodiments, the outer surface of the stylet is provided with depth markings so that the clinician can understand the extent to which it has penetrated the vertebral body.

In conducting initial animal experiments with a dual probe embodiment, the present inventors used a bipedicle approach as shown in FIG. 12, so that each probe approached the ION at angle δ of 45 to about 55 degrees. Since both the probes and the electrodes disposed thereon were essentially cylindrical, the inner faces 605, 615 of the electrodes produced an angle 2δ. Subsequent testing of the configuration of FIG. 12 revealed somewhat higher temperatures at the distal portion of the electrodes and somewhat lower temperatures near the proximal portions of the electrodes. Without wishing to be tied to a theory, it is believed that the shorter path between the distal regions produced a lower resistance region (as compared to more proximal inter-electrode regions) and so caused current to preferentially follow the path of the least resistance between the distal portions. Accordingly, the present inventors sought to improve upon the relatively uneven temperature profile produced by the electrode design of FIG. 12.

In accordance with the present invention the present inventors modified its electrode design to reduce the angle 2δ produces by the inner faces, so that the distance between the proximal end of the electrodes is more equal to the distance between the proximal end of the electrodes (i.e., the faces are more parallel). When the electrodes are provided in such a condition, their orientation reduces the significance of any path of least resistance, and so current flows more evenly across the face of each electrode, thereby providing even heating and greater control over the system.

Therefore, in accordance with the present invention, there is provided an intraosseous nerve denervation device, comprising:

    • a) a first probe having an active electrode and a first lead,
    • b) a second probe having a return electrode and a second lead,
    • c) means for creating first and second bores within a bone for accommodating the first and second probes,
    • d) a power supply capable of generating a voltage difference between the active and return electrodes, the supply having third and fourth leads,

wherein the first and third leads are in electrical connection, and the second and fourth leads are in electrical connection.

Preferably, the electrodes are disposed so that the angle 2δ produced by the inner faces is less than 60 degrees, more preferably no more than 30 degrees. Still more preferably, the angle is less than 1 degree. Most preferably, the inner faces are substantially parallel.

Now referring to FIG. 15, in some embodiments, substantially parallel electrodes are provided by using conical electrodes 501 that taper distally. In this FIG. 15, each cone electrode 501 has a distal end 503 having a diameter DD and a proximal end 505 having a diameter DP, wherein the distal end diameter DD is larger than the proximal end diameter DP. Preferably, the angle γ of the cone taper is substantially equal to the angle δ. In this condition, the inner faces of the conical electrodes will be essentially parallel to each other.

Therefore, in accordance with the present invention, there is provided intraosseous nerve denervation system comprising:

  • a) a first probe having a first electrode and a first lead in electrical connection with the first electrode,
    wherein the first electrode has a proximal end having a proximal diameter and a distal end having a distal diameter, and the proximal end diameter is less than the distal end diameter, and
  • b) a second probe having a first electrode and a first lead in electrical connection with the first electrode,
    wherein the first electrode has a proximal end having a proximal diameter and a distal end having a distal diameter, and the proximal end diameter is less than the distal end diameter, and
    wherein the first and second electrode are disposed so that the electrodes are parallel.

In FIG. 10, the conical shapes are frustoconical (i.e., they are portions of a cone). Frustoconical electrodes are desirable in situations where tissue charring needs to be avoided, as the relatively large diameter of the distal end of the electrode can not provide an avenue for high current density (relative to the proximal end of the electrode). Frustoconical electrodes are also desirable in situations where the probes are disposed at a relatively high angle δ, wherein the use of sharp tipped electrodes would substantially shorten the distance between the distal tips of the electrodes and thereby create an undesirable path of significantly less resistance.

In some embodiments, the frustoconical electrode is shaped so that the diameter of its distal end DD is between about 10% and 25% of the diameter of its proximal end DP. In some embodiments, the frustoconical nature of the electrode is provided by physically severing the sharp distal end of the electrode. In others, the frustoconical nature of the electrode is provided by insulating the sharp distal end of an electrode.

As noted above, when the probes are placed such that their corresponding electrodes are parallel to each other, the electric field produced by electrode activation is substantially uniform between the distal and proximal portions of the electrodes. However, as the probes are oriented at an angle from parallel, the electric field becomes strongest where the electrodes are closer together. In order to compensate for this non-uniform electric field, in some embodiments of the present invention, the distal ends of the electrodes are tapered. In this tapered state, the regions of the electrodes that are closer together (e.g., the tip) also have a smaller surface area (thereby reducing the electric field in that region), while the regions of the electrodes that are farther apart (e.g., the trunk) have a larger surface area (thereby increasing the electric field in that region). Typically, the effect is largely determined by the cone size, electrode spacing and tissue type therebetween.

In some preferred embodiments of the tapered electrode, and now referring to FIG. 16, the distal end of the electrode terminates in a sharp tip, so that the electrode has a more completely conical shape. Preferably, the conical electrode is shaped so that the diameter of its distal end is no more than 20% of the diameter of its proximal end, more preferably no more than 10%, more preferably no more than 1%. In addition to compensating for non-uniformity in the electric field, the sharp tip may also be adapted to penetrate the cortical shell of the vertebral body.

Now referring to FIG. 17, in some embodiments, current flows through an electrode having only a portion of the conical or frusto-conical shape. When electrodes of this embodiment, termed “sectored cones” face each other, their use is advantageous because they insure that current will flow the least distance, and so provide efficiency. The sectored cones of this embodiment can be produced by first manufacturing planar electrodes 511 and placing the planar electrode upon a conveniently angled probe surface 513. Alternatively, this embodiment can be produced by first manufacturing the conical electrode configuration of FIG. 15, and then masking a portion of the conical electrode with an insulating material. Unlike the embodiment of FIG. 15, this sectored cone embodiment requires careful alignment of the electrode faces and may require in vivo rotation of the electrodes to achieve the desired alignment.

Now referring to FIG. 18, in other embodiments, substantially parallel electrodes can be provided by using elbowed probes 531. The elbowed probes have a distal end 533 and a proximal end 535 meeting at an elbow 537. In some embodiments, the elbow may be produced during the manufacturing process (thereby requiring a smaller diameter probe in order to fit through the cannula). In other embodiments, the elbow is produced in vivo, such as through use of a pull-wire, a pivot or a memory metal disposed within the probe.

Now referring to FIG. 19, in some embodiments, first 551 and second 552 cannulae are each provided with a curved bore 553, 554 forming distal lateral openings 563,564 in their respective distal end portions 555, 556. When flexible probes 557, 558 containing an electrode 559,560 are passed through the curved bore, the distal end 561,562 of the probe likewise conforms to the curved bore, thereby forming an intra-probe angle ϵ determined by the proximal AP and distal AD axes of the probe. Preferably, this intra-probe angle is between 90 and 135 degrees. Preferably, the intra-probe angle is selected so that the distal axes AD of the probes exiting the cannulae form an angle of no more than 30 degrees, preferably no more than 10 degrees, more preferably form a substantially parallel relation.

Therefore, in accordance with the present invention, there is provided an intraosseous nerve denervation system, comprising:

  • a) a cannula having a longitudinal bore defining a first axis,
  • b) a stylet having an outer diameter adapted to be received within the longitudinal bore and a distal tip adapted to penetrate cortical bone, and
  • c) a first probe comprising:
  • d) an outer diameter adapted to be received within the longitudinal bore, and
    • i) a first electrode, and
    • ii) a lead in electrical connection with the first electrode.

Now referring to FIGS. 20a and 20b, in some embodiments, first 701 and second 751 cannulae are each provided with a curved bore 703, 753 in their respective distal portions 705, 755, wherein each bore has a proximal lateral opening 707,757. The apparatus further comprises first and second probes 711, 761, each containing an electrode 713,763. In some embodiments, the probe may sit in a distal region of the bore (as in FIG. 20a) during advance of the cannula. Once the target tissue region is reached, then probes are moved proximally (by, for example, a pull wire not shown) and exit the proximal lateral openings so that the inner faces 715, 765 of the electrodes face other.

Therefore, in accordance with the present invention, there is provided an intraosseous nerve denervation system, comprising:

  • a) a cannula having a longitudinal bore defining a first axis,
  • b) a stylet having an outer diameter adapted to be received within the longitudinal bore and a distal tip adapted to penetrate cortical bone, and
  • c) a first probe comprising:
    • i) an outer diameter adapted to be received within the longitudinal bore, and
    • ii) a first electrode, and
    • iii) a lead in electrical connection with the first electrode.

Now referring to FIGS. 21a and 21b, in some embodiments, at least one probe 801 comprises i) a distal portion 803 having an electrode 805 and ii) a proximal portion 807, the distal portion being pivotally attached to the proximal portion by pivot 809. In some embodiments, two probes having such pivotally attached electrodes are introduced through the cannulae in a first linear mode (shown in FIG. 21a) to produce an angle θ between the electrodes. Next, the respective pivots are actuated (by for example, a pull wire—not shown) to produce the angled configuration shown in FIG. 21b which reduces the angle θ between the electrodes. Preferably, the pivoting brings the electrodes into a substantially parallel relation.

Therefore, in accordance with the present invention, there is provided intraosseous nerve denervation system comprising:

  • a) a first probe having:
    • i) a distal portion having a first electrode,
    • ii) a proximal portion comprising a first lead in electrical connection with the first electrode, and
    • iii) a pivot pivotally connecting the proximal and distal portions of the probe.

In some embodiments, relatively even heating is provided by providing current density gradients. Now referring to FIG. 22, in some embodiments, first 821 and second 831 probes have first 823 and second 833 electrodes having a reverse conical shape. In particular, each electrode has a relatively thick distal portion 827, 837 and a relatively thin proximal portion 825, 835. When this probe is activated, it is believed that the current density of this electrode will vary axially, with a relatively high current density present at the proximal portion of each electrode (due to the smaller surface area) and a relatively low current density present at the distal portion of the electrode (due to the larger surface area). This current density gradient should provide a more even heating zone when the electrodes themselves are oriented at a significant angle, as the preference for tip heating (caused by the angled orientation of the electrodes) is substantially balanced by the higher current density at the proximal portions of the electrodes.

Therefore, in accordance with the present invention, there is provided an intraosseous nerve denervation system comprising:

  • a) a first probe having a first electrode and a first lead in electrical connection with the first electrode,
    wherein the first electrode has a proximal end having a proximal diameter and a distal end having a distal diameter, and
    wherein the proximal end diameter is less than the distal end diameter.

Current density gradients can also be produced by providing a plurality of electrodes on each probe. Now referring to FIG. 23, in some embodiments, first and second electrodes each have a plurality of electrodes. In particular, first probe 851 has first 853, second 854 and third 855 active electrodes, while second probe 861 has first 863, second 864 and third 865 return electrodes. The voltage across the probes can be selected so that there is increasing voltage (and therefore current) across the more widely spaced electrodes (i.e., V855-865<V854-864<V853-863). In some embodiments, the probes of FIG. 23 are driven by multiple voltage sources (i.e., a first voltage source for providing voltage between first active electrode 853 and first return electrode 863, etc.).

Therefore, in accordance with the present invention, there is provided a method of therapeutically treating a vertebral body having a BVN, comprising the steps of:

  • a) providing a first energy device having distal and proximal active electrodes,
  • b) providing a second energy device having distal and proximal return electrodes,
  • c) placing the first and second energy devices in the vertebral body to define a first distance between the distal active electrode and the distal return electrode, and a second distance between the proximal active electrode and the proximal return electrode, wherein the first distance is less than the second distance,
  • d) applying a first high frequency voltage between the distal active and distal return electrodes, and
    • applying a second high frequency voltage between the proximal active and proximal return electrodes, wherein the first high frequency voltage is less than the second high frequency voltage.

Because multiple voltage sources may add complexity to the device, in other embodiments, the differences in voltage may be provided by a single voltage source by using a poorly conductive electrode. In particular, in some embodiments thereof, the probe comprises an electrically conductive probe shaft and a plurality of spaced apart insulating jackets wherein the spacing produces the electrodes of FIG. 23. In this jacketed embodiment, the probe shaft can be made of a material that is a relatively poor electrical conductor (such as tantalum) so that, when a single driving force is applied between the jacketed probes, the voltage is highest at the proximal electrode 853, but loss due to the poor conductance produces a substantially lower voltage at distal electrode 855. This jacketed embodiment eliminates the need for multiple voltage sources.

In another dual probe approach, in some embodiments, and now referring to FIG. 24, there is provided an apparatus having first probe 871 having an active electrode 873, and a second 881 probe having a return electrode 883, wherein the ratio of the surface area of the active electrode to the surface area of the return electrode is very high,. i.e., at least 2:1 (more preferably at least 5:1). In this condition, the current density will be very high at the active electrode and very low at the return electrode, so that the total heating zone THZ will occur essentially only around the active electrode. Since this device heats essentially only at the active electrode, this device substantially mimics the heating profile of a monopolar electrode, but provides the desirable safety feature of locally directing the current to the return electrode.

Therefore, in accordance with the present invention, there is provided an intraosseous nerve denervation system comprising:

  • a) a first probe having:
    • i) an active electrode having a first surface area, and
    • ii) a first lead in electrical connection with the first electrode,
  • b) a second probe having:
    • i) a return electrode having a first surface area, and
    • ii) a second lead in electrical connection with the second electrode,
      wherein the first surface area is at least two times greater than the second surface area, and,
      means for creating first and second bores within a bone for accommodating the first and second probes.

Although the dual probe approach has many benefits, in other embodiments of the present invention, an articulated probe having both active and return electrodes may be used in accordance with the present invention.

Now referring to FIG. 25, there is provided a preferred articulated device according to the present invention. In preferred embodiments, this device 900 comprises a fixed probe 901 and a pivotable probe 951.

Fixed probe 901 comprises a shaft 903 having a longitudinal axis and a distal end portion 905 comprising sharpened distal tip 906 and a proximal end portion 907. Disposed near the distal end portion of the probe is first electrode 909. The fixed probe is designed so that the first electrode is placed in electrical connection with a first lead of a power supply. In this particular embodiment, the shaft has a longitudinal bore 911 running from the proximal end portion up to at least the first electrode. Disposed within the bore is a first wire (not shown) electrically connected at its first end to the first electrode and having a second end adapted to be electrically connected to a first lead of a power supply (not shown). The fixed probe also comprises a recess 927 forming a lateral opening in the shaft and designed to house the pivotable probe when in its undeployed mode.

Pivotable probe 951 comprises a shaft 953 having a longitudinal axis, a distal end portion 955, and a proximal end portion 957 pivotally attached to the fixed probe by pivot 961. The pivot allows the pivoting probe to pivot about the fixed probe. Disposed near the distal end portion of the pivotable probe is second electrode 963. The probe is designed so that the second electrode is placed in electrical connection with a second lead of the power supply.

The pivotable probe has an undeployed mode and a deployed mode. In the un-deployed mode, the pivotable probe is seated within the recess of the fixed probe so that the axis of its shaft is essentially in line with the axis of the fixed probe shaft. In this state, the pivotable probe essentially hides within the fixed probe. In the deployed mode, the pivotable probe extends at a significant angle from the fixed probe so that the axis of its shaft forms an angle of at least 10 degrees with the axis of the fixed probe shaft.

In some embodiments, a pusher rod is used to deploy the pivotable probe. Pusher rod 975 comprises a proximal handle (not shown) for gripping and a distal end portion 977 having a shape for accessing the bore of the fixed probe. Distal end portion has a tip 981 having a shape which, when advanced distally, can push the distal end portion of the pivotable probe laterally out of the recess.

Therefore, in accordance with the present invention, there is provided a device for denervating an ION in a bone, comprising:

    • a) a fixed probe having a first electrode thereon in electrical connection with the powder supply, and
    • b) a pivotable probe comprising a second electrode having a proximal portion pivotally engaged to the fixed probe.

In some embodiments, the pivotable device has both an active and a return electrode, and the device is introduced through a single pedicle. The location of these electrodes may vary depending upon the use of the pivotable device. For example, when the active electrode is located on the pivotable probe, the return electrode may be positioned in a location selected from the group consisting of:

a) a location on the fixed probe distal of the pivot (as in FIG. 25);

b) a location on the fixed probe proximal of the pivot;

c) a location on the pivotable probe located nearer the pivot; and

d) a location on the pusher rod.

In other embodiments, the locations of the active and return electrodes are reversed from those described above.

In general, it is desirable to operate the present invention in a manner that produces a peak temperature in the target tissue of between about 80° C. and 95° C. When the peak temperature is below 80° C., the off-peak temperatures may quickly fall below about 45° C. When the peak temperature is above about 95° C., the bone tissue exposed to that peak temperature may experience necrosis and produce charring. This charring reduces the electrical conductivity of the charred tissue, thereby making it more difficult to pass RF current through the target tissue beyond the char and to resistively heat the target tissue beyond the char. In some embodiments, the peak temperature is preferably between 86° C. and 94° C.

It is desirable to heat the volume of target tissue to a minimum temperature of at least 42° C. When the tissue experiences a temperature above 42° C., nerves within the target tissue may be desirably damaged. However, it is believed that denervation is a function of the total quantum of energy delivered to the target tissue, i.e., both exposure temperature and exposure time determine the total dose of energy delivered. Accordingly, if the temperature of the target tissue reaches only about 42° C., then it is believed that the exposure time of the volume of target tissue to that temperature should be at least about 30 minutes and preferably at least 60 minutes in order to deliver the dose of energy believed necessary to denervate the nerves within the target tissue.

Preferably, it is desirable to heat the volume of target tissue to a minimum temperature of at least 50° C. If the temperature of the target tissue reaches about 50° C., then it is believed that the exposure time of the volume of target tissue to that temperature need only be in the range of about 2 minutes to 10 minutes to achieve denervation.

More preferably, it is desirable to heat the volume of target tissue to a minimum temperature of at least 60° C. If the temperature of the target tissue reaches about 60° C., then it is believed that the exposure time of the volume of target tissue to that temperature need only be in the range of about 0.01 minutes to 1.5 minutes to achieve denervation, preferably 0.1 minutes to 0.25 minutes.

Typically, the period of time that an ION is exposed to therapeutic temperatures is in general related to the length of time in which the electrodes are activated. However, since it has been observed that the total heating zone remains relatively hot even after power has been turned off (and the electric field eliminated), the exposure time can include a period of time in which current is not running through the electrodes.

In general, the farther apart the electrodes, the greater the likelihood that the ION will be contained within the total heating zone. Therefore, in some embodiments, the electrodes are placed at least 5 mm apart, more preferably at least 10 mm apart. However, if the electrodes are spaced too far apart, the electric field takes on an undesirably extreme dumbbell shape. Therefore, in many preferred embodiments, the electrodes are placed apart a distance of between 5 mm and 25 mm, more preferably between 5 mm and 15 mm, more preferably between 10 mm and 15 mm.

In some embodiments, it is desirable to heat the target tissue so that at least about 1 cc of bone tissue experiences the minimum temperature. This volume corresponds to a sphere having a radius of about 0.6 cm. Alternatively stated, it is desirable to heat the target tissue so the minimum temperature is achieved by every portion of the bone within 0.6 cm of the point experiencing the peak temperature.

More preferably, it is desirable to heat the target tissue so that at least about 3 cc of bone experiences the minimum temperature. This volume corresponds to a sphere having a radius of about 1 cm.

In one preferred embodiment, the present invention provides a steady-state heated zone having a peak temperature of between 80° C. and 95° C. (and preferably between 86° C. and 94° C.), and heats at least 1 cc of bone (and preferably at least 3 cc of bone) to a temperature of at least 50° C. (and preferably 60° C.).

Therefore, in accordance with the present invention, there is provided a method of therapeutically treating a vertebral body having a BVN, comprising the steps of:

  • a) providing an energy device having an active and a return electrode,
  • a) inserting the active electrode into the vertebral body,
  • b) inserting the return electrode into the vertebral body, and
  • c) applying a sufficiently high frequency voltage difference between the active and return electrodes to generate a current therebetween to produce a total heating zone having a diameter of at least 0.5 cm and a steady state temperature of at least 50° C.

As noted above, a peak temperature below about 100° C. is desirable in order to prevent charring of the adjacent tissue, steam formation and tissue popping. In some embodiments, this is accomplished by providing the power supply with a feedback means that allows the peak temperature within the heating zone to be maintained at a desired target temperature, such as 90° C. In some embodiments, between about 24 watts and 30 watts of power is first supplied to the device in order to rapidly heat the relatively cool bone, with maximum amperage being obtained within about 10-15 seconds. As the bone is further heated to the target temperature, the feedback means gradually reduces the power input to the device to between about 6-10 watts.

If the active electrode has no active cooling means, it may become be subject to conductive heating by the heated tissue, and the resultant increased temperature in the electrode may adversely affect performance by charring the adjacent bone tissue. Accordingly, in some embodiments, a cool tip active electrode may be employed. The cooled electrode helps maintain the temperature of the electrode at a desired temperature. Cooled tip active electrodes are known in the art. Alternatively, the power supply may be designed to provided a pulsed energy input. It has been found that pulsing the current favorably allows heat to dissipate from the electrode tip, and so the active electrode stays relatively cooler.

The following section relates to the general structure of preferred energy devices in accordance with the present invention:

The apparatus according to the present invention comprises an electro surgical probe having a shaft with a proximal end, a distal end, and at least one active electrode at or near the distal end. A connector is provided at or near the proximal end of the shaft for electrically coupling the active electrode to a high frequency voltage source. In some embodiments, a return electrode coupled to the voltage source is spaced a sufficient distance from the active electrode to substantially avoid or minimize current shorting therebetween. The return electrode may be provided integral with the shaft of the probe or it may be separate from the shaft

In preferred embodiments, the electrosurgical probe or catheter will comprise a shaft or a handpiece having a proximal end and a distal end which supports one or more electrode terminal(s). The shaft or handpiece may assume a wide variety of configurations, with the primary purpose being to mechanically support the active electrode and permit the treating physician to manipulate the electrode from a proximal end of the shaft. The shaft may be rigid or flexible, with flexible shafts optionally being combined with a generally rigid external tube for mechanical support. Flexible shafts may be combined with pull wires, shape memory actuators, and other known mechanisms for effecting selective deflection of the distal end of the shaft to facilitate positioning of the electrode array. The shaft will usually include a plurality of wires or other conductive elements running axially therethrough to permit connection of the electrode array to a connector at the proximal end of the shaft.

Preferably, the shaft may be a rigid needle that is introduced through a percutaneous penetration in the patient. However, for endoscopic procedures within the spine, the shaft will have a suitable diameter and length to allow the surgeon to reach the target site (e.g., a disc) by delivering the shaft through the thoracic cavity, the abdomen or the like. Thus, the shaft will usually have a length in the range of about 5.0 to 30.0 cm, and a diameter in the range of about 0.2 mm to about 10 mm. In any of these embodiments, the shaft may also be introduced through rigid or flexible endoscopes.

The probe will include one or more active electrode(s) for applying electrical energy to tissues within the spine. The probe may include one or more return electrode(s), or the return electrode may be positioned on the patient's back, as a dispersive pad. In either embodiment, sufficient electrical energy is applied through the probe to the active electrode(s) to either necrose the blood supply or nerves within the vertebral body.

The electrosurgical instrument may also be a catheter that is delivered percutaneously and/or endoluminally into the patient by insertion through a conventional or specialized guide catheter, or the invention may include a catheter having an active electrode or electrode array integral with its distal end. The catheter shaft may be rigid or flexible, with flexible shafts optionally being combined with a generally rigid external tube for mechanical support. Flexible shafts may be combined with pull wires, shape memory actuators, and other known mechanisms for effecting selective deflection of the distal end of the shaft to facilitate positioning of the electrode or electrode array. The catheter shaft will usually include a plurality of wires or other conductive elements running axially therethrough to permit connection of the electrode or electrode array and the return electrode to a connector at the proximal end of the catheter shaft. The catheter shaft may include a guide wire for guiding the catheter to the target site, or the catheter may comprise a steerable guide catheter. The catheter may also include a substantially rigid distal end portion to increase the torque control of the distal end portion as the catheter is advanced further into the patient's body. Specific deployment means will be described in detail in connection with the figures hereinafter.

In some embodiments, the electrically conductive wires may run freely inside the catheter bore in an unconstrained made, or within multiple lumens within the catheter bore.

The tip region of the instrument may comprise many independent electrode terminals designed to deliver electrical energy in the vicinity of the tip. The selective application of electrical energy is achieved by connecting each individual electrode terminal and the return electrode to a power source having independently controlled or current limited channels. The return electrode(s) may comprise a single tubular member of conductive material proximal to the electrode array. Alternatively, the instrument may comprise an array of return electrodes at the distal tip of the instrument (together with the active electrodes) to maintain the electric current at the tip. The application of high frequency voltage between the return electrode(s) and the electrode array results in the generation of high electric field intensities at the distal tips of the electrode terminals with conduction of high frequency current from each individual electrode terminal to the return electrode. The current flow from each individual electrode terminal to the return electrode(s) is controlled by either active or passive means, or a combination thereof, to deliver electrical energy to the surrounding conductive fluid while minimizing energy delivery to surrounding (non-target) tissue.

Temperature probes associated with the apparatus may preferably be disposed on or within the electrode carrier; between the electrodes (preferred in bipolar embodiments); or within the electrodes (preferred for monopolar embodiments). In some embodiments wherein the electrodes are placed on either side of the ION, a temperature probe is disposed between the electrodes or in the electrodes. In alternate embodiments, the deployable portion of the temperature probe comprises a memory metal.

The electrode terminal(s) are preferably supported within or by an inorganic insulating support positioned near the distal end of the instrument shaft. The return electrode may be located on the instrument shaft, on another instrument or on the external surface of the patient (i.e., a dispersive pad). The close proximity of the dual needle design to the intraosseus nerve makes a bipolar design more preferable because this minimizes the current flow through non-target tissue and surrounding nerves. Accordingly, the return electrode is preferably either integrated with the instrument body, or another instrument located in close proximity thereto. The proximal end of the instrument(s) will include the appropriate electrical connections for coupling the return electrode(s) and the electrode terminal(s) to a high frequency power supply, such as an electrosurgical generator.

In some embodiments, the active electrode(s) have an active portion or surface with surface geometries shaped to promote the electric field intensity and associated current density along the leading edges of the electrodes. Suitable surface geometries may be obtained by creating electrode shapes that include preferential sharp edges, or by creating asperities or other surface roughness on the active surface(s) of the electrodes. Electrode shapes according to the present invention can include the use of formed wire (e.g., by drawing round wire through a shaping die) to form electrodes with a variety of cross-sectional shapes, such as square, rectangular, L or V shaped, or the like. Electrode edges may also be created by removing a portion of the elongate metal electrode to reshape the cross-section. For example, material can be ground along the length of a round or hollow wire electrode to form D or C shaped wires, respectively, with edges facing in the cutting direction. Alternatively, material can be removed at closely spaced intervals along the electrode length to form transverse grooves, slots, threads or the like along the electrodes. In other embodiments, the probe can be sectored so that a given circumference comprises an electrode region and an inactive region. In some embodiments, the inactive region is masked.

The return electrode is typically spaced proximally from the active electrode(s) a suitable. In most of the embodiments described herein, the distal edge of the exposed surface of the return electrode is spaced about 5 to 25 mm from the proximal edge of the exposed surface of the active electrode(s), in dual needle insertions. Of course, this distance may vary with different voltage ranges, the electrode geometry and depend on the proximity of tissue structures to active and return electrodes. The return electrode will typically have an exposed length in the range of about 1 to 20 mm.

The application of a high frequency voltage between the return electrode(s) and the electrode terminal(s) for appropriate time intervals effects modifying the target tissue.

The present invention may use a single active electrode terminal or an array of electrode terminals spaced around the distal surface of a catheter or probe. In the latter embodiment, the electrode array usually includes a plurality of independently current-limited and/or power-controlled electrode terminals to apply electrical energy selectively to the target tissue while limiting the unwanted application of electrical energy to the surrounding tissue and environment resulting from power dissipation into surrounding electrically conductive fluids, such as blood, normal saline, and the like. The electrode terminals may be independently current-limited by isolating the terminals from each other and connecting each terminal to a separate power source that is isolated from the other electrode terminals. Alternatively, the electrode terminals may be connected to each other at either the proximal or distal ends of the catheter to form a single wire that couples to a power source.

In one configuration, each individual electrode terminal in the electrode array is electrically insulated from all other electrode terminals in the array within said instrument and is connected to a power source which is isolated from each of the other electrode terminals in the array or to circuitry which limits or interrupts current flow to the electrode terminal when low resistivity material (e.g., blood) causes a lower impedance path between the return electrode and the individual electrode terminal. The isolated power sources for each individual electrode terminal may be separate power supply circuits having internal impedance characteristics which limit power to the associated electrode terminal when a low impedance return path is encountered. By way of example, the isolated power source may be a user selectable constant current source. In this embodiment, lower impedance paths will automatically result in lower resistive heating levels since the heating is proportional to the square of the operating current times the impedance. Alternatively, a single power source may be connected to each of the electrode terminals through independently actuatable switches, or by independent current limiting elements, such as inductors, capacitors, resistors and/or combinations thereof. The current limiting elements may be provided in the instrument, connectors, cable, controller or along the conductive path from the controller to the distal tip of the instrument. Alternatively, the resistance and/or capacitance may occur on the surface of the active electrode terminal(s) due to oxide layers which form selected electrode terminals (e.g., titanium or a resistive coating on the surface of metal, such as platinum).

In a preferred aspect of the invention, the active electrode comprises an electrode array having a plurality of electrically isolated electrode terminals disposed over a contact surface, which may be a planar or non-planar surface and which may be located at the distal tip or over a lateral surface of the shaft, or over both the tip and lateral surface(s). The electrode array will include at least two and preferably more electrode terminals, and may further comprise a temperature sensor. In a preferred aspect, each electrode terminal will be connected to the proximal connector by an electrically isolated conductor disposed within the shaft. The conductors permit independent electrical coupling of the electrode terminals to a high frequency power supply and control system with optional temperature monitor for operation of the probe. The control system preferably incorporate active and/or passive current limiting structures, which are designed to limit current flow when the associated electrode terminal is in contact with a low resistance return path back to the return electrode.

The use of such electrode arrays in electrosurgical procedures is particularly advantageous as it has been found to limit the depth of tissue necrosis without substantially reducing power delivery. The voltage applied to each electrode terminal causes electrical energy to be imparted to any body structure which is contacted by, or comes into close proximity with, the electrode terminal, where a current flow through all low electrical impedance paths is preferably but not necessarily limited. Since some of the needles are hollow, a conductive fluid could be added through the needle and into the bone structure for the purposes of lowering the electrical impedance and fill the spaces in the cancellous bone to make them better conductors to the needle.

It should be clearly understood that the invention is not limited to electrically isolated electrode terminals, or even to a plurality of electrode terminals. For example, the array of active electrode terminals may be connected to a single lead that extends through the catheter shaft to a power source of high frequency current. Alternatively, the instrument may incorporate a single electrode that extends directly through the catheter shaft or is connected to a single lead that extends to the power source. The active electrode(s) may have ball shapes, twizzle shapes, spring shapes, twisted metal shapes, cone shapes, annular or solid tube shapes or the like. Alternatively, the electrode(s) may comprise a plurality of filaments, rigid or flexible brush electrode(s), side-effect brush electrode(s) on a lateral surface of the shaft, coiled electrode(s) or the like.

The voltage difference applied between the return electrode(s) and the electrode terminal(s) will be at high or radio frequency, typically between about 50 kHz and 20 MHz, usually being between about 100 kHz and 2.5 MHz, preferably being between about 400 kHz and 1000 kHz, often less than 600 kHz, and often between about 500 kHz and 600 kHz. The RMS (root mean square) voltage applied will usually be in the range from about 5 volts to 1000 volts, preferably being in the range from about 10 volts to 200 volts, often between about 20 to 100 volts depending on the electrode terminal size, the operating frequency and the operation mode of the particular procedure. Lower peak-to-peak voltages will be used for tissue coagulation, thermal heating of tissue, or collagen contraction and will typically be in the range from 50 to 1500, preferably 100 to 1000 and more preferably 120 to 400 volts peak-to-peak. As discussed above, the voltage is usually delivered continuously with a sufficiently high frequency (e.g., on the order of 50 kHz to 20 MHz) (as compared with e.g., lasers claiming small depths of necrosis, which are generally pulsed about 10 to 20 Hz). In addition, the sine wave duty cycle (i.e., cumulative time in any one-second interval that energy is applied) is preferably on the order of about 100% for the present invention, as compared with pulsed lasers which typically have a duty cycle of about 0.0001%.

The preferred power source of the present invention delivers a high frequency current selectable to generate average power levels ranging from several milliwatts to tens of watts per electrode, depending on the volume of target tissue being heated, and/or the maximum allowed temperature selected for the instrument tip. The power source allows the user to select the power level according to the specific requirements of a particular procedure.

The power source may be current limited or otherwise controlled so that undesired heating of the target tissue or surrounding (non-target) tissue does not occur. In a presently preferred embodiment of the present invention, current limiting inductors are placed in series with each independent electrode terminal, where the inductance of the inductor is in the range of 10 uH to 50,000 uH, depending on the electrical properties of the target tissue, the desired tissue heating rate and the operating frequency. Alternatively, capacitor-inductor (LC) circuit structures may be employed, as described previously in U.S. Pat. No. 5,697,909. Additionally, current limiting resistors may be selected. Preferably, microprocessors are employed to monitor the measured current and control the output to limit the current.

The area of the tissue treatment surface can vary widely, and the tissue treatment surface can assume a variety of geometries, with particular areas and geometries being selected for specific applications. The geometries can be planar, concave, convex, hemispherical, conical, linear “in-line” array or virtually any other regular or irregular shape. Most commonly, the active electrode(s) or electrode terminal(s) will be formed at the distal tip of the electro surgical instrument shaft, frequently being planar, disk-shaped, or hemispherical surfaces for use in reshaping procedures or being linear arrays for use in cutting. Alternatively or additionally, the active electrode(s) may be formed on lateral surfaces of the electrosurgical instrument shaft (e.g., in the manner of a spatula), facilitating access to certain body structures in endoscopic procedures.

The devices of the present invention may be suitably used for insertion into any hard tissue in the human body. In some embodiments, the hard tissue is bone. In other embodiments, the hard tissue is cartilage. In preferred embodiments when bone is selected as the tissue of choice, the bone is a vertebral body. Preferably, the present invention is adapted to puncture the hard cortical shell of the bone and penetrate at least a portion of the underlying cancellous bone. In some embodiments, the probe advances into the bone to a distance of at least ⅓ of the cross-section of the bone defined by the advance of the probe. In some embodiments, the present invention is practiced in vertebral bodies substantially free of tumors. In others, the present invention is practiced in vertebral bodies having tumors.

Therefore, in accordance with the present invention, there is provided a method of therapeutically treating a healthy vertebral body having a BVN, comprising the steps of:

  • a) providing an energy device having an active and a return electrode,
  • b) inserting the active electrode into the healthy vertebral body,
  • c) inserting the return electrode into the healthy vertebral body,
  • d) placing the active electrode on a first side of the healthy vertebral body and the return electrode on a second side of the healthy vertebral body, and

applying a sufficiently high frequency voltage difference between the active and return electrodes to generate a current therebetween to produce a total heating zone to therapeutically heat the BVN.

In some embodiments using two separate probes, the device of the present invention enters the hard tissue (preferably bone, more preferably the vertebral body) through two access points. In preferred embodiments, the pair of separate probes is adapted to denervate the BVN and enter through separate pedicles transpedicularly. In other embodiments, the pair of separate probes each enters the vertebral body extrapedicularly. In other embodiments, a first of the pair of separate probes enters the vertebral body extrapedicularly and the second enters the vertebral body transpedicularly. In embodiments using a single articulated device, the device enters via a single pedicle.

Now referring to FIG. 26, in some embodiments, the target region of the BVN is located within the cancellous portion of the bone (i.e., to the interior of the outer cortical bone region), and proximal to the junction J of the BVN having a plurality of branches. Treatment in this region is advantageous because only a single portion of the BVN need be effectively treated to denervate the entire system. In contrast, treatment of the BVN in locations more downstream than the junction require the denervation of each branch.

Therefore, in accordance with the present invention, there is provided a method of therapeutically treating a vertebral body having an outer cortical bone region and an inner cancellous bone region, and a BVN having a trunk extending from the outer cortical bone region into the inner cancellous region and a branches extending from the trunk to define a BVN junction, comprising the steps of:

  • a) inserting an energy device into the vertebral body, and
  • b) exclusively depositing energy within the inner cancellous bone region of the vertebral body between, but exclusive of the BVN junction and the outer cortical bone region, to denervate the BVN.

Typically, treatment in accordance with this embodiment can be effectuated by placing the electrodes in the region of the vertebral body located between 60% (point A) and 90% (point B) of the distance between the anterior and posterior ends of the vertebral body, as shown in FIG. 26.

EXAMPLE I

This prophetic example describes a preferred dual probe embodiment of the present invention.

First, after induction of an appropriate amount of a local anesthesia, the human patient is placed in a prone position on the table. The C-arm of an X-ray apparatus is positioned so that the X-rays are perpendicular to the axis of the spine. This positioning provides a lateral view of the vertebral body, thereby allowing the surgeon to view the access of the apparatus into the vertebral body.

Next, a cannulated stylet comprising an inner stylet and an outer cannula are inserted into the skin above each of the respective pedicles so that the distal tip of each stylet is in close proximity to the respective pedicle.

Next, the probe is advanced interiorly into the body so that the stylet tips bores through the skin, into and through the pedicle, and then into the vertebral body. The stylet is advanced until the tips reach the anterior-posterior midline of the vertebral body.

Next, the stylet is withdrawn and probe is inserted into the cannula and advanced until the first and second electrodes thereof each reach the midline of the vertebral body. The location of the two probes is shown from various perspectives in FIG. 27a-d.

Next, the power supply is activated to provide a voltage between the first and second electrodes. The amount of voltage across the electrodes is sufficient to produce an electric current between the first and second electrodes. This current provides resistive heating of the tissue disposed between the electrodes in an amount sufficient to raise the temperature of the local portion of the BVN to at least 45° C., thereby denervating the BVN.

EXAMPLE II

This example describes the efficacy of heating a large zone of a vertebral body with a bipolar energy device.

A pair of probes were inserted into a vertebral body of a porcine cadaver so that the tips of the electrodes were located substantially at the midline and separated by about 4 mm. Each electrode had a cylindrical shape, a length of about 20 mm, and a diameter of about 1.65 mm2 (16 gauge) to produce a surface area of about 100 mm2.

Next, and now referring to FIGS. 28a and 28b, thermocouples 0-14 were placed within the vertebral body at the 15 locations. Thermocouples 0-4 were placed halfway between the electrode tips and were separated by a distance of 2 mm. Thermocouples 5-9 were placed about at the midpoint between the probe tips, and were vertically separated by a distance of 2 mm Thermocouples 10-14 were placed along the distal portion of the probe and were separated by a distance of 5 mm.

Next, about 57 volts of energy was applied across the electrodes, and the temperature rise in the tissue was recorded at the thermocouple sites. These temperatures are provided in FIGS. 29a-c. In general, the temperature at each site rose somewhat steadily from about 22° C. to its peak temperature in about 200-300 seconds, whereupon feedback controls maintained the peak temperatures.

FIGS. 30a and 30b provide the peak temperatures recorded by each thermocouple. Analysis of the results in FIGS. 17a and 17b reveals that peak temperatures of between about 80° C. and 95° C. were able to be sustained over substantial distances. In particular, a temperature of 79.4 degrees was reached about 10 mm along the electrode (T11); temperatures of between 76.7 and 80.3° C. were reached at a depth of about 4 mm within the tissue (T5 and T9); and a temperature of 76.8° C. was reached about 10 mm along the electrode (T3).

The positive results provided by this example has great significance to the problem of therapeutically heating IONs, and the BVN in particular. In particular, the results of thermocouples T5-9 indicates that if an ION were located along the z-axis within 2 mm of the presumed center of the IRZ, then the ION could be sufficiently treated to at least 80° C. Similarly, the results of thermocouples T0-4 indicates that as much as a 16 mm length of ION could be sufficiently treated to at least 80° C. Lastly, the results of thermocouples. T 10-14 indicate that the ION could be off-center laterally in the IRZ by as much as 2 mm and at least about 10 mm of its length could be sufficiently treated to at least 80 C.

EXAMPLE III

This embodiment describes a preferred articulated probe embodiment of the present invention.

The initial steps described above in Example I are carried out so that the articulated probe is poised on the patient's skin and held in place by a ratchet type gun. See FIG. 31a.

Next, the distal end of the articulated probe is inserted into the skin above a pedicle so that the distal end of the fixed probe is in close proximity, to the pedicle.

Now referring to FIG. 31b, the probe is advanced interiorly into the body so that the distal tip bores through the skin, into and through the pedicle, and then into the vertebral body. The distal tip is advanced until it reaches about 30% beyond the anterior-posterior midline of the vertebral body.

Now referring to FIG. 31c, the distal end of the pusher rod is inserted into the bore of the fixed probe and advanced until the angled portion of the pusher rod contacts the angled portion of the pivotable probe, thereby nudging the pivotable probe out of the recess. The pivotable probe is now in a partially deployed mode.

Now referring to FIG. 31d, the apparatus is slightly withdrawn from the body. As this occurs, the bone disposed between the pivotable and fixed probes prevents the pivotable probe from withdrawing along with the fixed probe, but rather forces open the pivoting means, thereby bringing the axis of the pivotable probe to a position substantially normal to the axis of the fixed probe. The pivotable probe is now in extended mode.

Next, the power supply is activated to provide a voltage between the first and second electrodes. The amount of voltage across the electrodes is sufficient to produce an electric current between the first and second electrodes. This current provides resistive heating of the tissue disposed between the electrodes in an amount sufficient to raise the temperature of the local portion of the BVN to at least 45° C., thereby denervating the BVN.

Next, the fixed probe is pushed forward to bring the pivotable probe back into the recess.

Now referring to FIGS. 31e, the probe is removed from the body.

EXAMPLE IV

Now referring to FIG. 32, there is provided a dual articulated needle embodiment of the present invention, wherein the articulated needles are each advanced down the pedicles of the vertebral body, and each of the pivotable probes are deployed at an angle of less than 90 degrees, so that the electrodes thereon align themselves in an essentially parallel relationship. Because the electric field produced by this embodiment is relatviely even between the electrodes, the resulting total heating zone is also desirably homogeneous. Because the electrodes deploy in the central posterior portion of the vertebral body, the BVN is desirably denervated near its trunk.

Claims

1. A method of therapeutically treating a vertebral body having an outer cortical bone region, an inner cancellous bone region, and a basivertebral nerve BVN, comprising the steps of:

providing a probe configured to deploy an energy device having an electrode;
the probe comprising a longitudinal bore extending from a proximal end of the probe toward a distal end of the probe;
the probe comprising a recess in communication with said bore, said recess forming a lateral opening at or near the distal end of the probe;
the probe further comprising a pivotable member;
the pivotable member having a fixed end pivotably secured to the probe at a distal location within the recess of the probe, and a free end configured to be seated in said recess;
wherein the pivotable member comprises an undeployed mode where the free end extends proximally from the fixed end within said recess, and a deployed mode where the free end is configured to pivot about said fixed end and extend outward from said probe;
articulating the pivotable member from the undeployed mode to the deployed mode to facilitate delivery of the energy device along a path associated with the free end of the pivotable member into the cancellous bone region of the vertebral body; and
applying a sufficiently high frequency voltage to the electrode to heat the BVN.

2. A method as recited in claim 1, the BVN having a trunk extending from the outer cortical bone region and into the inner cancellous bone region and branches extending from the trunk to define a BVN junction, wherein therapeutically heating the BVN comprises:

depositing therapeutic energy within the inner cancellous bone region of the vertebral body.

3. The method of claim 2, wherein the therapeutic energy is deposited in a region of the vertebral body located between 60% and 90% of the distance between the posterior and anterior ends of the vertebral body.

4. The method of claim 3, wherein said therapeutic energy is deposited in a region of the vertebral body located between 60% and 90% of the distance from the anterior wall to the posterior wall of the vertebral body.

5. The method of claim 2, wherein said therapeutic energy deposited includes a region that is proximal of the BVN junction.

6. The method of claim 2, wherein said therapeutic energy is deposited within a region that is at least 1 cm in diameter.

7. The method of claim 2, wherein said therapeutic energy deposited comprises a steady-state heated zone having a peak temperature of between 80 degrees C. and 95 degrees C.

8. The method of claim 7, wherein said steady-state heated zone heats at least 1 cc of bone to a temperature of at least 50 degrees C.

9. The method of claim 2, wherein the method is performed to treat pain in a patient diagnosed with pain.

10. The method of claim 1, wherein the method is performed to treat pain in a patient diagnosed with pain.

11. The method of claim 1, wherein the pivotable member in the undeployed mode is entirely contained within said recess.

12. The method of claim 1, wherein articulating the pivotable member from the undeployed mode to the deployed mode comprises advancing a member distally along said bore to push the free end of the of the pivotable member laterally out the recess.

13. The method of claim 1, wherein the free end of the pivotable member deploys pivotably outward from the recess into the cancellous bone region.

14. A method of therapeutically treating a vertebral body having an outer cortical bone region, an inner cancellous bone region, and a basivertebral nerve BVN, comprising the steps of:

providing a probe configured to deploy an energy device comprising an electrode;
the probe comprising a longitudinal bore extending from a proximal end of the probe toward a distal end of the probe;
the probe comprising a recess in communication with said bore, said recess forming an opening at or near the distal end of the probe;
the probe further comprising a pivotable member;
the pivotable member having a fixed end secured to the probe at a location within the recess of the probe, and a free end configured to be extended out of the opening of the probe;
wherein the pivotable member comprises an undeployed mode where the free end is not in an articulated configuration, and a deployed mode where the free end is configured to extend outward from the opening of said probe into the articulated configuration;
articulating the pivotable member from the undeployed mode to the deployed mode to facilitate delivery of the energy device along a path associated with the free end of the pivotable member into the cancellous bone region of the vertebral body; and
applying a sufficiently high frequency voltage to the electrode to heat the BVN to a temperature between 80 degrees Celsius and 95 degrees Celsius and sufficient to denervate the BVN,
wherein the frequency of the voltage is between 400 kHz and 600 kHz,
wherein the probe comprises a sharp distal tip, and
wherein the probe comprises a temperature sensor.

15. The method of claim 14, wherein the electrode comprises an active electrode and wherein the probe further comprises a return electrode.

16. The method of claim 14, wherein the applied high frequency voltage is configured to form a heating zone having a diameter of between 0.5 cm and 2.0 cm.

17. The method of claim 14, wherein the probe has a length between 5 and 30 cm and a diameter between 0.2 mm and 10 mm.

18. The method of claim 14, further comprising:

piercing skin of a patient with a cannulated needle, the cannulated needle comprising a cannula and a stylet inserted within the cannula until a distal tip of the stylet extends beyond a distal opening of the cannula;
advancing the cannulated needle so that the distal tip of the stylet enters within the cancellous bone region of the vertebral body;
withdrawing the stylet from the cannula; and
inserting at least a distal portion of the probe through a bore of the cannula and out of the distal opening of the cannula.
Referenced Cited
U.S. Patent Documents
3565062 February 1971 Kuris
3822708 July 1974 Zilber
3845771 November 1974 Vice
3920021 November 1975 Hiltebrandt
3938502 February 17, 1976 Born
3997408 December 14, 1976 Barba et al.
4044774 August 30, 1977 Corgin et al.
4116198 September 26, 1978 Roos
4311154 January 19, 1982 Sterzer et al.
4312364 January 26, 1982 Convert et al.
4378806 April 5, 1983 Henley-Cohn
4448198 May 15, 1984 Turner
4449528 May 22, 1984 Auth et al.
4462408 July 31, 1984 Silverstein et al.
4528979 July 16, 1985 Marchenko et al.
4530360 July 23, 1985 Durate
4569351 February 11, 1986 Tang
4573448 March 4, 1986 Kambin
4586512 May 6, 1986 Do-huu
4601296 July 22, 1986 Yerushalmi
4612940 September 23, 1986 Kasevich et al.
4657017 April 14, 1987 Sorochenko
4662383 May 5, 1987 Sogawa et al.
4671293 June 9, 1987 Shalov
4676258 June 30, 1987 Inokuchi et al.
4679561 July 14, 1987 Doss
4681122 July 21, 1987 Winters et al.
4750499 June 14, 1988 Hoffer
4754757 July 5, 1988 Feucht
4757820 July 19, 1988 Itoh
4774967 October 4, 1988 Zanakis et al.
4800899 January 31, 1989 Elliott
4813429 March 21, 1989 Eshel et al.
4841977 June 27, 1989 Griffith et al.
4907589 March 13, 1990 Cosman
4924863 May 15, 1990 Sterzer
4936281 June 26, 1990 Stasz
4950267 August 21, 1990 Ishihara et al.
4951677 August 28, 1990 Crowley et al.
4955377 September 11, 1990 Lennox et al.
4959063 September 25, 1990 Kojima
4961435 October 9, 1990 Kitagawa et al.
4963142 October 16, 1990 Loertscher
4966144 October 30, 1990 Rochkind et al.
4967765 November 6, 1990 Turner et al.
4976711 December 11, 1990 Parins et al.
4977902 December 18, 1990 Sekino et al.
5000185 March 19, 1991 Yock
5002058 March 26, 1991 Martinelli
5002059 March 26, 1991 Crowley et al.
5007437 April 16, 1991 Sterzer
5025778 June 25, 1991 Silverstein et al.
5031618 July 16, 1991 Mullett
5061266 October 29, 1991 Hakky
5070879 December 10, 1991 Herres
RE33791 January 7, 1992 Carr
5078736 January 7, 1992 Behl
5080660 January 14, 1992 Buelna
5084043 January 28, 1992 Hertzmann et al.
5090414 February 25, 1992 Takano
5098431 March 24, 1992 Rydell
5106376 April 21, 1992 Mononen et al.
5108404 April 28, 1992 Scholten et al.
5131397 July 21, 1992 Crowley et al.
5147355 September 15, 1992 Friedman et al.
5156157 October 20, 1992 Valenta, Jr. et al.
5158536 October 27, 1992 Sekins et al.
5161533 November 10, 1992 Press et al.
5167231 December 1, 1992 Matsui
5186177 February 16, 1993 O'Donnell et al.
5190540 March 2, 1993 Lee
5190546 March 2, 1993 Jervis
5201729 April 13, 1993 Hertzmann et al.
5207672 May 4, 1993 Martinelli et al.
5209748 May 11, 1993 Daikuzono
5222953 June 29, 1993 Dowlatshahi
5226430 July 13, 1993 Spears et al.
5242439 September 7, 1993 Larsen et al.
5255679 October 26, 1993 Imran
5271408 December 21, 1993 Breyer et al.
5273026 December 28, 1993 Wilk
5281213 January 25, 1994 Milder et al.
5281215 January 25, 1994 Milder et al.
5282468 February 1, 1994 Klepinski
5292321 March 8, 1994 Lee
5295484 March 22, 1994 Marcus et al.
5300085 April 5, 1994 Yock
5304214 April 19, 1994 DeFord et al.
5305756 April 26, 1994 Entrekin et al.
5314463 May 24, 1994 Camps et al.
5320617 June 14, 1994 Leach
5324255 June 28, 1994 Pasafaro et al.
5325860 July 5, 1994 Seward et al.
5342292 August 30, 1994 Nita et al.
5342357 August 30, 1994 Nardella
5342409 August 30, 1994 Mullett
5344435 September 6, 1994 Turner et al.
5345940 September 13, 1994 Seward et al.
5348554 September 20, 1994 Imran et al.
5350377 September 27, 1994 Winston et al.
5351691 October 4, 1994 Brommersma
5366443 November 22, 1994 Eggers et al.
5366490 November 22, 1994 Edwards et al.
5368031 November 29, 1994 Cline et al.
5368035 November 29, 1994 Hamm et al.
5368557 November 29, 1994 Nita et al.
5368558 November 29, 1994 Nita
5370675 December 6, 1994 Edwards et al.
5370678 December 6, 1994 Edwards et al.
5372138 December 13, 1994 Crowley et al.
5374265 December 20, 1994 Sand
5383876 January 24, 1995 Nardella
5385148 January 31, 1995 Lesh et al.
5385544 January 31, 1995 Edwards et al.
5391197 February 21, 1995 Burdette et al.
5391199 February 21, 1995 Ben-Haim
5405376 April 11, 1995 Mulier et al.
5411527 May 2, 1995 Alt
5417719 May 23, 1995 Hull et al.
5419767 May 30, 1995 Eggers et al.
5421338 June 6, 1995 Crowley
5423811 June 13, 1995 Imran et al.
5431649 July 11, 1995 Mulier et al.
5433739 July 18, 1995 Cosman et al.
D361555 August 22, 1995 Bettin et al.
5437661 August 1, 1995 Rieser
5441499 August 15, 1995 Fritzsch
5443463 August 22, 1995 Stern
5447509 September 5, 1995 Millis et al.
5449380 September 12, 1995 Chin
5454373 October 3, 1995 Koger et al.
5458596 October 17, 1995 Lax et al.
5458597 October 17, 1995 Edwards et al.
5471988 December 5, 1995 Fujio et al.
5472441 December 5, 1995 Edwards et al.
5474530 December 12, 1995 Passafaro et al.
5484432 January 16, 1996 Sand
5486170 January 23, 1996 Winston et al.
5501703 March 26, 1996 Holsheimer et al.
5505730 April 9, 1996 Edwarrds
5514130 May 7, 1996 Baker
5524624 June 11, 1996 Tepper et al.
5526815 June 18, 1996 Granz et al.
5529580 June 25, 1996 Hagino et al.
5540679 July 30, 1996 Fram et al.
5540681 July 30, 1996 Strul et al.
5540684 July 30, 1996 Hassler, Jr.
5545161 August 13, 1996 Imran
5560362 October 1, 1996 Silwa, Jr. et al.
5565005 October 15, 1996 Erickson et al.
5569242 October 29, 1996 Lax et al.
5571088 November 5, 1996 Lennox et al.
5571147 November 5, 1996 Sluijter et al.
5575772 November 19, 1996 Lennox
5575788 November 19, 1996 Baker et al.
5588432 December 31, 1996 Crowley
5596988 January 28, 1997 Markle et al.
5601526 February 11, 1997 Chapelon et al.
5606974 March 4, 1997 Castellano et al.
5609151 March 11, 1997 Mulier et al.
5620479 April 15, 1997 Diederich
5628317 May 13, 1997 Starkebaum et al.
5630426 May 20, 1997 Shmulewitz et al.
5630837 May 20, 1997 Crowley
5643319 July 1, 1997 Green et al.
5643330 July 1, 1997 Holshiemer et al.
5647361 July 15, 1997 Damadian
5647871 July 15, 1997 Levine et al.
5658278 August 19, 1997 Imran et al.
5672173 September 30, 1997 Gough et al.
5681282 October 28, 1997 Eggers et al.
5683366 November 4, 1997 Eggers et al.
5685839 November 11, 1997 Baker et al.
5687729 November 18, 1997 Schaetzle
5688267 November 18, 1997 Panescu
5693052 December 2, 1997 Weaver
5697281 December 16, 1997 Eggers et al.
5697536 December 16, 1997 Eggers et al.
5697882 December 16, 1997 Eggers et al.
5697909 December 16, 1997 Eggers et al.
5697927 December 16, 1997 Imran et al.
5700262 December 23, 1997 Acosta et al.
5718231 February 17, 1998 Chen et al.
5720286 February 24, 1998 Chapelon et al.
5720287 February 24, 1998 Chapelon et al.
5722403 March 3, 1998 McGee et al.
5725494 March 10, 1998 Brisken
5728062 March 17, 1998 Brisken
5730706 March 24, 1998 Garnies
5733315 March 31, 1998 Burdette et al.
5735280 April 7, 1998 Sherman et al.
5735811 April 7, 1998 Brisken
5735846 April 7, 1998 Fleischman et al.
5735847 April 7, 1998 Gough et al.
5738680 April 14, 1998 Mueller et al.
5741249 April 21, 1998 Moss et al.
5743904 April 28, 1998 Edwards
5746737 May 5, 1998 Saadat
5752969 May 19, 1998 Cunci et al.
5755663 May 26, 1998 Johnson et al.
5762066 June 9, 1998 Law et al.
5762616 June 9, 1998 Talish
5766153 June 16, 1998 Eggers et al.
5766231 June 16, 1998 Erickson et al.
5776092 July 7, 1998 Farin et al.
5785705 July 28, 1998 Baker
5800378 September 1, 1998 Edwards et al.
5800429 September 1, 1998 Edwards
5800432 September 1, 1998 Swanson
5807237 September 15, 1998 Tindel
5807391 September 15, 1998 Wijkamp
5807392 September 15, 1998 Eggers
5807395 September 15, 1998 Mulier et al.
5810764 September 22, 1998 Eggers et al.
5817021 October 6, 1998 Reichenberger
5824021 October 20, 1998 Rise
5840031 November 24, 1998 Crowley
5843019 December 1, 1998 Eggers et al.
5843021 December 1, 1998 Edwards et al.
5844092 December 1, 1998 Presta et al.
5846218 December 8, 1998 Brisken et al.
5849011 December 15, 1998 Jones et al.
5855576 January 5, 1999 LeVeen et al.
5860951 January 19, 1999 Eggers et al.
5865788 February 2, 1999 Edwards et al.
5865801 February 2, 1999 Houser
5868740 February 9, 1999 LeVeen et al.
5871469 February 16, 1999 Eggers et al.
5871470 February 16, 1999 McWha
5871481 February 16, 1999 Kannenberg et al.
5873855 February 23, 1999 Eggers et al.
5873877 February 23, 1999 McGaffigan et al.
5876398 March 2, 1999 Mulier et al.
5888198 March 30, 1999 Eggers et al.
5891095 April 6, 1999 Eggers et al.
5895370 April 20, 1999 Edwards et al.
5902272 May 11, 1999 Eggers et al.
5902308 May 11, 1999 Murphy
5904681 May 18, 1999 West, Jr.
5906613 May 25, 1999 Mulier et al.
5916213 June 29, 1999 Haissaguerre et al.
5916214 June 29, 1999 Cosio
5919188 July 6, 1999 Shearon et al.
5931805 August 3, 1999 Brisken
5935123 August 10, 1999 Edwards et al.
5938582 August 17, 1999 Ciamacco et al.
5941722 August 24, 1999 Chen
5941876 August 24, 1999 Nardella et al.
5944715 August 31, 1999 Goble et al.
5948007 September 7, 1999 Starkebaum et al.
5948008 September 7, 1999 Daikuzono
5954716 September 21, 1999 Sharkey et al.
5964727 October 12, 1999 Edwards et al.
5967988 October 19, 1999 Briscoe et al.
5976105 November 2, 1999 Marcove et al.
5983141 November 9, 1999 Sluijter et al.
5997497 December 7, 1999 Nita et al.
6001095 December 14, 1999 de la Rama et al.
6007533 December 28, 1999 Casscells et al.
6007570 December 28, 1999 Sharkey et al.
6012457 January 11, 2000 Lesh
6014588 January 11, 2000 Fitz
6016452 January 18, 2000 Kasevich
6016809 January 25, 2000 Mulier et al.
6017356 January 25, 2000 Frederick et al.
6019776 February 1, 2000 Preissman et al.
6022334 February 8, 2000 Edwards et al.
6024733 February 15, 2000 Eggers et al.
6024740 February 15, 2000 Lesh et al.
6030374 February 29, 2000 McDaniel
6030402 February 29, 2000 Thompson et al.
6032673 March 7, 2000 Langberg et al.
6032674 March 7, 2000 Eggers et al.
6033411 March 7, 2000 Preissman et al.
6035238 March 7, 2000 Ingle et al.
6038480 March 14, 2000 Hrdlicka et al.
6045532 April 4, 2000 Eggers et al.
6046187 April 4, 2000 Berde et al.
6047214 April 4, 2000 Mueller et al.
6050995 April 18, 2000 Durgin
6053172 April 25, 2000 Hovda et al.
6053909 April 25, 2000 Shadduck
6063078 May 16, 2000 Wittkampf
6063079 May 16, 2000 Hovda et al.
6066134 May 23, 2000 Eggers et al.
6066139 May 23, 2000 Ryan et al.
6068642 May 30, 2000 Johnson et al.
6071279 June 6, 2000 Whayne et al.
6073051 June 6, 2000 Sharkey et al.
6074352 June 13, 2000 Hynynen et al.
6086585 July 11, 2000 Hovda et al.
6090105 July 18, 2000 Zepeda et al.
6095149 August 1, 2000 Sharkey et al.
6099499 August 8, 2000 Ciamacco
6099514 August 8, 2000 Sharkey et al.
6102046 August 15, 2000 Weinstein et al.
6104957 August 15, 2000 Alo et al.
6105581 August 22, 2000 Eggers et al.
6106454 August 22, 2000 Berg et al.
6109268 August 29, 2000 Thapliyal et al.
6112122 August 29, 2000 Schwardt et al.
6113597 September 5, 2000 Eggers et al.
6117101 September 12, 2000 Diederich et al.
6117109 September 12, 2000 Eggers et al.
6117128 September 12, 2000 Gregory
6120467 September 19, 2000 Schallhorn
6120502 September 19, 2000 Michelson
6122549 September 19, 2000 Sharkey et al.
6126682 October 3, 2000 Ashley et al.
6137209 October 24, 2000 Dahlberg et al.
6139545 October 31, 2000 Utley et al.
6142992 November 7, 2000 Cheng et al.
6143019 November 7, 2000 Motamedi et al.
6146380 November 14, 2000 Racz et al.
6149620 November 21, 2000 Baker et al.
6159194 December 12, 2000 Eggers et al.
6159208 December 12, 2000 Hovda et al.
6161048 December 12, 2000 Sluijter et al.
6164283 December 26, 2000 Lesh
6165172 December 26, 2000 Farley et al.
6168593 January 2, 2001 Sharkey et al.
6169924 January 2, 2001 Meloy et al.
6171239 January 9, 2001 Humphrey
6176857 January 23, 2001 Ashley
6179824 January 30, 2001 Eggers et al.
6179836 January 30, 2001 Eggers et al.
6179858 January 30, 2001 Squire et al.
6183469 February 6, 2001 Thapliyal et al.
6190381 February 20, 2001 Olsen et al.
6190383 February 20, 2001 Schmaltz et al.
6193715 February 27, 2001 Wrublewski et al.
6203542 March 20, 2001 Ellsberry et al.
6206842 March 27, 2001 Tu et al.
6210393 April 3, 2001 Brisken
6210402 April 3, 2001 Olsen et al.
6210415 April 3, 2001 Bester
6216704 April 17, 2001 Ingle et al.
6221038 April 24, 2001 Brisken
6224592 May 1, 2001 Eggers et al.
6228046 May 8, 2001 Brisken
6228078 May 8, 2001 Eggers et al.
6228082 May 8, 2001 Baker et al.
6231516 May 15, 2001 Keilman et al.
6231528 May 15, 2001 Kaufman et al.
6231571 May 15, 2001 Ellman et al.
6231615 May 15, 2001 Preissman
6233488 May 15, 2001 Hess
6235020 May 22, 2001 Cheng et al.
6235024 May 22, 2001 Tu
6238391 May 29, 2001 Olsen et al.
6238393 May 29, 2001 Mulier et al.
6241665 June 5, 2001 Negus et al.
6241725 June 5, 2001 Cosman
6245064 June 12, 2001 Lesh
6246912 June 12, 2001 Sluijter et al.
6248345 June 19, 2001 Goldenheim et al.
6254553 July 3, 2001 Lidgren et al.
6254599 July 3, 2001 Lesh et al.
6254600 July 3, 2001 Willink et al.
6258086 July 10, 2001 Ashley et al.
6259952 July 10, 2001 Sluijter
6261311 July 17, 2001 Sharkey et al.
6264650 July 24, 2001 Hovda et al.
6264651 July 24, 2001 Underwood et al.
6264652 July 24, 2001 Eggers et al.
6264659 July 24, 2001 Ross et al.
6267770 July 31, 2001 Truwit
6270498 August 7, 2001 Michelson
6277112 August 21, 2001 Underwood et al.
6277122 August 21, 2001 McGahan et al.
6280441 August 28, 2001 Ryan
6283961 September 4, 2001 Underwood et al.
6287114 September 11, 2001 Meller et al.
6287272 September 11, 2001 Brisken et al.
6287304 September 11, 2001 Eggers et al.
6290715 September 18, 2001 Sharkey et al.
6292699 September 18, 2001 Simon et al.
6296619 October 2, 2001 Brisken et al.
6296636 October 2, 2001 Cheng et al.
6296638 October 2, 2001 Davison et al.
6305378 October 23, 2001 Lesh et al.
6309387 October 30, 2001 Eggers et al.
6309420 October 30, 2001 Preissman
6312408 November 6, 2001 Eggers et al.
6312426 November 6, 2001 Goldberg et al.
6319241 November 20, 2001 King et al.
6322549 November 27, 2001 Eggers et al.
6348055 February 19, 2002 Preissman
6355032 March 12, 2002 Hovda et al.
6356790 March 12, 2002 Maguire et al.
6361531 March 26, 2002 Hissong
6363937 April 2, 2002 Hovda et al.
6368292 April 9, 2002 Ogden et al.
6379351 April 30, 2002 Thapliyal et al.
6383190 May 7, 2002 Preissman
6391025 May 21, 2002 Weinstein et al.
6416507 July 9, 2002 Eggers et al.
6416508 July 9, 2002 Eggers et al.
6423059 July 23, 2002 Hanson et al.
6426339 July 30, 2002 Berde et al.
6428491 August 6, 2002 Weiss
6432103 August 13, 2002 Ellsberry et al.
6436060 August 20, 2002 Talish
6436098 August 20, 2002 Michelson
6447448 September 10, 2002 Ishikawa et al.
6451013 September 17, 2002 Bays et al.
6454727 September 24, 2002 Bubank et al.
6461350 October 8, 2002 Underwood et al.
6461354 October 8, 2002 Olsen et al.
6464695 October 15, 2002 Hovda et al.
6468270 October 22, 2002 Hovda et al.
6468274 October 22, 2002 Alleyne et al.
6470220 October 22, 2002 Kraus et al.
6478793 November 12, 2002 Cosman et al.
6482201 November 19, 2002 Olsen et al.
6485271 November 26, 2002 Tack
6487446 November 26, 2002 Hill et al.
6491893 December 10, 2002 Babich
6493592 December 10, 2002 Leonard et al.
6494902 December 17, 2002 Hoey et al.
6500173 December 31, 2002 Underwood et al.
6505075 January 7, 2003 Weiner
6508839 January 21, 2003 Lambrecht et al.
6524261 February 25, 2003 Talish et al.
6537306 March 25, 2003 Burdette et al.
6527759 March 4, 2003 Tachibana et al.
6540741 April 1, 2003 Underwood et al.
6544261 April 8, 2003 Ellsberry et al.
6557559 May 6, 2003 Eggers et al.
6558385 May 6, 2003 McClurken et al.
6558390 May 6, 2003 Cragg
6560486 May 6, 2003 Osorio et al.
6562033 May 13, 2003 Shah et al.
6575968 June 10, 2003 Eggers et al.
6575969 June 10, 2003 Rittman, III et al.
6575979 June 10, 2003 Cragg
6578579 June 17, 2003 Burnside et al.
6582423 June 24, 2003 Thapliyal et al.
6585656 July 1, 2003 Masters
6589237 July 8, 2003 Woloszko et al.
6592559 July 15, 2003 Pakter et al.
6595990 July 22, 2003 Weinstein et al.
6599288 July 29, 2003 Maguire et al.
6602248 August 5, 2003 Sharps et al.
6604003 August 5, 2003 Fredricks et al.
6607502 August 19, 2003 Maguire et al.
6607529 August 19, 2003 Jones et al.
6608502 August 19, 2003 Aoki et al.
6622731 September 23, 2003 Daniel et al.
6632193 October 14, 2003 Davison et al.
6632220 October 14, 2003 Eggers et al.
6645202 November 11, 2003 Pless et al.
6648883 November 18, 2003 Francischelli et al.
6659106 December 9, 2003 Hovda et al.
6663627 December 16, 2003 Francischelli et al.
6673063 January 6, 2004 Brett
6689086 February 10, 2004 Nita et al.
6689125 February 10, 2004 Keith et al.
6692450 February 17, 2004 Coleman
6699240 March 2, 2004 Francischelli
6699242 March 2, 2004 Heggeness
6709432 March 23, 2004 Ferek-Patric
6718208 April 6, 2004 Hill et al.
6723087 April 20, 2004 O'Neill et al.
6726684 April 27, 2004 Woloszko et al.
6736810 May 18, 2004 Hoey et al.
6736835 May 18, 2004 Pellegrino et al.
6745079 June 1, 2004 King
6746447 June 8, 2004 Davison et al.
6749604 June 15, 2004 Eggers et al.
6758846 July 6, 2004 Goble et al.
6770071 August 3, 2004 Woloszko et al.
6772012 August 3, 2004 Ricart et al.
6773431 August 10, 2004 Eggers et al.
6795737 September 21, 2004 Gielen et al.
6827715 December 7, 2004 Francischelli et al.
6827716 December 7, 2004 Ryan et al.
6832996 December 21, 2004 Woloszko et al.
6837887 January 4, 2005 Woloszko et al.
6837888 January 4, 2005 Ciarrocca et al.
6852091 February 8, 2005 Edwards et al.
6863672 March 8, 2005 Reiley et al.
6875219 April 5, 2005 Arramon et al.
6881214 April 19, 2005 Cosman et al.
6896674 May 24, 2005 Woloszko et al.
6896675 May 24, 2005 Leung et al.
6907884 June 21, 2005 Pellegrino et al.
6915806 July 12, 2005 Pacek et al.
6922579 July 26, 2005 Taimisto et al.
6923813 August 2, 2005 Phillips et al.
6936046 August 30, 2005 Hissong et al.
6955674 October 18, 2005 Eick et al.
6960204 November 1, 2005 Eggers et al.
6962589 November 8, 2005 Mulier et al.
6974453 December 13, 2005 Woloszko et al.
6980849 December 27, 2005 Sasso
6989010 January 24, 2006 Francischelli et al.
6997941 February 14, 2006 Sharkey et al.
7048743 May 23, 2006 Miller et al.
7065408 June 20, 2006 Herman et al.
7081122 July 25, 2006 Reiley et al.
7090672 August 15, 2006 Underwood et al.
7104989 September 12, 2006 Skarda
7131969 November 7, 2006 Hovda et al.
7177678 February 13, 2007 Osorio et al.
7179255 February 20, 2007 Lettice et al.
7186234 March 6, 2007 Dahla et al.
7192428 March 20, 2007 Eggers et al.
7201731 April 10, 2007 Lundquist et al.
7201750 April 10, 2007 Eggers et al.
7211055 May 1, 2007 Diederich et al.
7217268 May 15, 2007 Eggers et al.
7250048 July 31, 2007 Francischelli et al.
7258690 August 21, 2007 Sutton et al.
7270659 September 18, 2007 Ricart et al.
7270661 September 18, 2007 Dahla et al.
7276063 October 2, 2007 Davison et al.
7294127 November 13, 2007 Leung et al.
7305264 December 4, 2007 Larson et al.
7306596 December 11, 2007 Hillier et al.
7318823 January 15, 2008 Sharps et al.
7326203 February 5, 2008 Papineau et al.
7331956 February 19, 2008 Hovda et al.
7331957 February 19, 2008 Woloszko et al.
RE40156 March 18, 2008 Sharps et al.
7346391 March 18, 2008 Osorio et al.
7386350 June 10, 2008 Vilims
7387625 June 17, 2008 Hovda et al.
7393351 July 1, 2008 Woloszko et al.
7422585 September 9, 2008 Eggers et al.
7429262 September 30, 2008 Woloszko et al.
7435247 October 14, 2008 Woloszko et al.
7435250 October 14, 2008 Francischelli et al.
7442191 October 28, 2008 Hovda et al.
7468059 December 23, 2008 Eggers et al.
7480533 January 20, 2009 Cosman et al.
7502652 March 10, 2009 Gaunt et al.
7503921 March 17, 2009 Siegel
7507236 March 24, 2009 Eggers et al.
7546164 June 9, 2009 King
7553307 June 30, 2009 Bleich et al.
7553309 June 30, 2009 Buysse et al.
7555343 June 30, 2009 Bleich
7593778 September 22, 2009 Chandran et al.
7645277 January 12, 2010 McClurken et al.
7678111 March 16, 2010 Mulier et al.
7708733 May 4, 2010 Sanders et al.
7738968 June 15, 2010 Bleich
7740631 June 22, 2010 Bleich et al.
7749218 July 6, 2010 Pellegrino et al.
7749220 July 6, 2010 Schmaltz et al.
7819826 October 26, 2010 Diederich et al.
7819869 October 26, 2010 Godara et al.
7824398 November 2, 2010 Woloszko et al.
7824404 November 2, 2010 Godara et al.
7846156 December 7, 2010 Malis et al.
7850685 December 14, 2010 Kunis et al.
7857813 December 28, 2010 Schmitz et al.
7896870 March 1, 2011 Arless et al.
7901403 March 8, 2011 Woloszko et al.
7909827 March 22, 2011 Reiley et al.
7914526 March 29, 2011 Lehmann et al.
7917222 March 29, 2011 Osorio et al.
7918849 April 5, 2011 Bleich et al.
7918874 April 5, 2011 Siegal
7945331 May 17, 2011 Vilims
7951140 May 31, 2011 Arless et al.
7963915 June 21, 2011 Bleich
7969634 June 28, 2011 Sennett
8021401 September 20, 2011 Carl et al.
8025688 September 27, 2011 Diederich et al.
8034052 October 11, 2011 Podhajsky
8062290 November 22, 2011 Buysse et al.
8066702 November 29, 2011 Rittman, III et al.
8083736 December 27, 2011 McClurken et al.
8100896 January 24, 2012 Podhajsky
8128633 March 6, 2012 Linderman et al.
8162933 April 24, 2012 Francischelli et al.
8172846 May 8, 2012 Brunnett et al.
8182477 May 22, 2012 Orszulak et al.
8192424 June 5, 2012 Woloszko et al.
8192435 June 5, 2012 Bleich et al.
8265747 September 11, 2012 Rittman, III et al.
8282628 October 9, 2012 Paul et al.
8292887 October 23, 2012 Woloszko et al.
8323279 December 4, 2012 Dahla et al.
8348946 January 8, 2013 McClurken et al.
8355799 January 15, 2013 Marion et al.
8361067 January 29, 2013 Pellegrino et al.
8414509 April 9, 2013 Diederich et al.
8414571 April 9, 2013 Pellegrino et al.
8419730 April 16, 2013 Pellegrino et al.
8419731 April 16, 2013 Pellegrino et al.
8425507 April 23, 2013 Pellegrino et al.
8444640 May 21, 2013 Demarais et al.
8454594 June 4, 2013 Demarais et al.
8475449 July 2, 2013 Werneth et al.
8486063 July 16, 2013 Werneth et al.
8504147 August 6, 2013 Deem et al.
8535309 September 17, 2013 Pellegrino et al.
8579903 November 12, 2013 Carl
8597301 December 3, 2013 Mitchell
8613744 December 24, 2013 Pellegrino et al.
8617156 December 31, 2013 Werneth et al.
8623014 January 7, 2014 Pellegrino et al.
8628528 January 14, 2014 Pellegrino et al.
8644941 February 4, 2014 Rooney et al.
8657814 February 25, 2014 Werneth et al.
8676309 March 18, 2014 Deem et al.
8690884 April 8, 2014 Linderman et al.
8747359 June 10, 2014 Pakter et al.
8747398 June 10, 2014 Behnke
8758349 June 24, 2014 Germain et al.
8771276 July 8, 2014 Linderman
8774913 July 8, 2014 Demarais et al.
8774924 July 8, 2014 Weiner
8795270 August 5, 2014 Drake
8808161 August 19, 2014 Gregg et al.
8808284 August 19, 2014 Pellegrino et al.
8821488 September 2, 2014 Stewart et al.
8845631 September 30, 2014 Werneth et al.
8864760 October 21, 2014 Kramer et al.
8882755 November 11, 2014 Leung et al.
8882759 November 11, 2014 Manley et al.
8882764 November 11, 2014 Pellegrino et al.
8894658 November 25, 2014 Linderman et al.
8915949 December 23, 2014 Diederich et al.
8926620 January 6, 2015 Chasmawala et al.
8968288 March 3, 2015 Brannan
8989859 March 24, 2015 Deem et al.
8992522 March 31, 2015 Pellegrino et al.
8992523 March 31, 2015 Pellegrino et al.
9017325 April 28, 2015 Pellegrino et al.
9023038 May 5, 2015 Pellegrino et al.
9028488 May 12, 2015 Goshayeshgar
9028538 May 12, 2015 Paul et al.
9039701 May 26, 2015 Pellegrino et al.
9044245 June 2, 2015 Condie et al.
9044254 June 2, 2015 Ladtkow et al.
9044575 June 2, 2015 Beasley et al.
9095359 August 4, 2015 Robert et al.
9113896 August 25, 2015 Mulier et al.
9113911 August 25, 2015 Sherman
9113925 August 25, 2015 Smith et al.
9119647 September 1, 2015 Brannan
9119650 September 1, 2015 Brannan et al.
9125671 September 8, 2015 Germain et al.
9131597 September 8, 2015 Taft et al.
9151680 October 6, 2015 Brannan
9155895 October 13, 2015 Wacnik et al.
9161735 October 20, 2015 Bradford et al.
9161805 October 20, 2015 Isenberg
9161814 October 20, 2015 Brannan et al.
9168078 October 27, 2015 Linderman et al.
9168085 October 27, 2015 Juzkiw
9173676 November 3, 2015 Pellegrino et al.
9173700 November 3, 2015 Godara et al.
9179970 November 10, 2015 Utley et al.
9186197 November 17, 2015 McKay
9192308 November 24, 2015 Brannan et al.
9198684 December 1, 2015 Arthur et al.
9226756 January 5, 2016 Teisen et al.
9237916 January 19, 2016 Crainich et al.
9238139 January 19, 2016 Degiorgio et al.
9241729 January 26, 2016 Juntz et al.
9241760 January 26, 2016 Godara et al.
9247992 February 2, 2016 Ladtkow et al.
9247993 February 2, 2016 Ladtkow et al.
9248278 February 2, 2016 Crosby et al.
9248289 February 2, 2016 Bennett et al.
9254168 February 9, 2016 Palanker
9254386 February 9, 2016 Lee et al.
9259241 February 16, 2016 Pellegrino et al.
9259248 February 16, 2016 Leuthardt et al.
9259269 February 16, 2016 Ladtkow et al.
9259569 February 16, 2016 Brounstein et al.
9259577 February 16, 2016 Kaula et al.
9265522 February 23, 2016 Pellegrino et al.
9265557 February 23, 2016 Sherman et al.
9277969 March 8, 2016 Brannan et al.
9282988 March 15, 2016 Goshayeshgar
9289607 March 22, 2016 Su et al.
9295517 March 29, 2016 Peyman et al.
9295841 March 29, 2016 Fang et al.
9301723 April 5, 2016 Brannan et al.
9301804 April 5, 2016 Bonn
9302117 April 5, 2016 De Vincentiis
9308036 April 12, 2016 Robinson
9308045 April 12, 2016 Kim et al.
9314252 April 19, 2016 Schaller et al.
9314613 April 19, 2016 Mashiach
9314618 April 19, 2016 Imran et al.
9333144 May 10, 2016 Baxter et al.
9333339 May 10, 2016 Weiner
9333361 May 10, 2016 Li et al.
9333373 May 10, 2016 Imran
9339655 May 17, 2016 Carbunaru
9345530 May 24, 2016 Ballakur et al.
9345537 May 24, 2016 Harrison et al.
9345538 May 24, 2016 Deem et al.
9351739 May 31, 2016 Mahoney et al.
9358067 June 7, 2016 Lee et al.
9358396 June 7, 2016 Holley
9364286 June 14, 2016 Werneth et al.
9370348 June 21, 2016 Tally et al.
9370392 June 21, 2016 Sharonov
9370398 June 21, 2016 Ladtkow et al.
9375274 June 28, 2016 Reid
9375275 June 28, 2016 Lee et al.
9375278 June 28, 2016 Robert et al.
9375279 June 28, 2016 Brannan
9375283 June 28, 2016 Arts et al.
9381024 July 5, 2016 Globerman et al.
9381045 July 5, 2016 Donner et al.
9381050 July 5, 2016 Lee et al.
9381359 July 5, 2016 Parramon et al.
9387094 July 12, 2016 Manrique et al.
9393416 July 19, 2016 Rooney et al.
9398931 July 26, 2016 Wittenberger et al.
9399144 July 26, 2016 Howard
9403038 August 2, 2016 Tyler
9409023 August 9, 2016 Burdick et al.
9414884 August 16, 2016 Faehndrich et al.
9421064 August 23, 2016 Pellegrino et al.
9421123 August 23, 2016 Lee et al.
9421371 August 23, 2016 Pless et al.
9421378 August 23, 2016 Lian et al.
9439693 September 13, 2016 Childs et al.
9439721 September 13, 2016 Werneth et al.
9445859 September 20, 2016 Childs et al.
9446229 September 20, 2016 Omar-Pasha
9446235 September 20, 2016 Su et al.
9452286 September 27, 2016 Cowan et al.
9456836 October 4, 2016 Boling et al.
9457182 October 4, 2016 Koop
9468485 October 18, 2016 Wittenberger et al.
9468495 October 18, 2016 Kunis et al.
9474906 October 25, 2016 Sachs et al.
9486279 November 8, 2016 Pellegrino et al.
9486447 November 8, 2016 Peterson et al.
9486621 November 8, 2016 Howard et al.
9492657 November 15, 2016 Gerber
9492664 November 15, 2016 Peterson
9504372 November 29, 2016 Kim
9504518 November 29, 2016 Condie et al.
9504530 November 29, 2016 Hartmann et al.
9504818 November 29, 2016 Moffitt et al.
9511229 December 6, 2016 Bradley
9511231 December 6, 2016 Kent et al.
9517200 December 13, 2016 Bleier
9526507 December 27, 2016 Germain
9526551 December 27, 2016 Linderman
9532828 January 3, 2017 Condie et al.
9549772 January 24, 2017 Carl
9550041 January 24, 2017 Bedell
9555037 January 31, 2017 Podhajsky
9566449 February 14, 2017 Perryman et al.
9572976 February 21, 2017 Howard et al.
9572986 February 21, 2017 Moffitt
9579518 February 28, 2017 Gertner
9597148 March 21, 2017 Olson
RE46356 April 4, 2017 Pellegrino
9610117 April 4, 2017 Germain
9649116 May 16, 2017 Germain
9687255 June 27, 2017 Sennett et al.
9724107 August 8, 2017 Pellegrino et al.
9724151 August 8, 2017 Edidin
9730707 August 15, 2017 Sasaki et al.
9770280 September 26, 2017 Diederich et al.
9775627 October 3, 2017 Patel et al.
9782221 October 10, 2017 Srinivasan
9795802 October 24, 2017 Mohamed et al.
9848944 December 26, 2017 Sutton et al.
10028753 July 24, 2018 Pellegrino et al.
10111704 October 30, 2018 Pellegrino et al.
10265099 April 23, 2019 Pellegrino et al.
10272271 April 30, 2019 Diederich et al.
10357258 July 23, 2019 Patel et al.
10390877 August 27, 2019 Heggeness et al.
10456187 October 29, 2019 Edidin
10463380 November 5, 2019 Purdy et al.
10463423 November 5, 2019 Sutton et al.
10470781 November 12, 2019 Purdy et al.
10478246 November 19, 2019 Pellegrino et al.
10517611 December 31, 2019 Patel et al.
10588691 March 17, 2020 Pellegrino et al.
10589131 March 17, 2020 Diederich et al.
10603522 March 31, 2020 Diederich et al.
20010001314 May 17, 2001 Davison et al.
20010001811 May 24, 2001 Burney et al.
20010020167 September 6, 2001 Woloszko et al.
20010023348 September 20, 2001 Ashley et al.
20010025176 September 27, 2001 Ellsberry et al.
20010025177 September 27, 2001 Woloszko et al.
20010027295 October 4, 2001 Dulak et al.
20010029370 October 11, 2001 Hodva et al.
20010029373 October 11, 2001 Baker et al.
20010029393 October 11, 2001 Tierney et al.
20010032001 October 18, 2001 Ricart et al.
20010047167 November 29, 2001 Heggeness
20010049522 December 6, 2001 Eggers et al.
20010049527 December 6, 2001 Cragg
20010051802 December 13, 2001 Woloszko et al.
20010053885 December 20, 2001 Gielen et al.
20010056280 December 27, 2001 Underwood et al.
20020016600 February 7, 2002 Cosman
20020019626 February 14, 2002 Sharkey et al.
20020026186 February 28, 2002 Woloszko et al.
20020049438 April 25, 2002 Sharkey et al.
20020095144 July 18, 2002 Carl
20020052600 May 2, 2002 Davison et al.
20020068930 June 6, 2002 Tasto et al.
20020095151 July 18, 2002 Dahla et al.
20020095152 July 18, 2002 Ciarrocca et al.
20020099366 July 25, 2002 Dahla et al.
20020111661 August 15, 2002 Cross et al.
20020115945 August 22, 2002 D'Luzansky et al.
20020120259 August 29, 2002 Lettice
20020147444 October 10, 2002 Shah et al.
20020151885 October 17, 2002 Underwood et al.
20020188284 December 12, 2002 To et al.
20020188290 December 12, 2002 Sharkey et al.
20020193708 December 19, 2002 Thompson et al.
20020193789 December 19, 2002 Underwood et al.
20030009164 January 9, 2003 Woloszko et al.
20030014047 January 16, 2003 Woloszko et al.
20030014088 January 16, 2003 Fang et al.
20030028147 February 6, 2003 Aves et al.
20030028189 February 6, 2003 Woloszko et al.
20030040742 February 27, 2003 Underwood et al.
20030055418 March 20, 2003 Tasto et al.
20030069569 April 10, 2003 Burdette et al.
20030083592 May 1, 2003 Faciszewski
20030084907 May 8, 2003 Pacek et al.
20030097126 May 22, 2003 Woloszko et al.
20030097129 May 22, 2003 Davison et al.
20030130655 July 10, 2003 Woloszko et al.
20030139652 July 24, 2003 Kang et al.
20030158545 August 21, 2003 Hovda et al.
20030181963 September 25, 2003 Pellegrino et al.
20030208194 November 6, 2003 Hovda et al.
20030216725 November 20, 2003 Woloszko et al.
20030216726 November 20, 2003 Eggers et al.
20030225364 December 4, 2003 Kraft
20040006339 January 8, 2004 Underwood et al.
20040024399 February 5, 2004 Sharps et al.
20040054366 March 18, 2004 Davison et al.
20040064023 April 1, 2004 Thomas et al.
20040064136 April 1, 2004 Crombie et al.
20040064137 April 1, 2004 Pellegrino et al.
20040068242 April 8, 2004 McGuckin, Jr.
20040082942 April 29, 2004 Katzman
20040087937 May 6, 2004 Eggers et al.
20040116922 June 17, 2004 Hovda et al.
20040120891 June 24, 2004 Hill et al.
20040133124 July 8, 2004 Bates et al.
20040162559 August 19, 2004 Arramon
20040186544 September 23, 2004 King
20040193151 September 30, 2004 To et al.
20040220577 November 4, 2004 Cragg et al.
20040225228 November 11, 2004 Ferree
20040230190 November 18, 2004 Dahla et al.
20050004634 January 6, 2005 Ricart et al.
20050010095 January 13, 2005 Stewart et al.
20050010203 January 13, 2005 Edwards et al.
20050010205 January 13, 2005 Hovda et al.
20050055096 March 10, 2005 Serhan et al.
20050177210 August 11, 2005 Leung et al.
20050177211 August 11, 2005 Leung et al.
20050182417 August 18, 2005 Pagano
20050192564 September 1, 2005 Cosman et al.
20050209659 September 22, 2005 Pellegrino et al.
20050234445 October 20, 2005 Conquergood et al.
20050261754 November 24, 2005 Woloszko
20050267552 December 1, 2005 Conquergood et al.
20050278007 December 15, 2005 Godara
20050283148 December 22, 2005 Janssen et al.
20060004369 January 5, 2006 Patel et al.
20060052743 March 9, 2006 Reynolds
20060064101 March 23, 2006 Arramon
20060095026 May 4, 2006 Ricart et al.
20060095028 May 4, 2006 Bleich
20060106375 May 18, 2006 Werneth et al.
20060106376 May 18, 2006 Godara et al.
20060122458 June 8, 2006 Bleich
20060129101 June 15, 2006 McGuckin
20060178670 August 10, 2006 Woloszko et al.
20060206128 September 14, 2006 Conquergood et al.
20060206129 September 14, 2006 Conquergood et al.
20060206130 September 14, 2006 Conquergood et al.
20060206132 September 14, 2006 Conquergood et al.
20060206133 September 14, 2006 Conquergood et al.
20060206134 September 14, 2006 Conquergood et al.
20060206166 September 14, 2006 Weiner
20060229625 October 12, 2006 Truckai et al.
20060253117 November 9, 2006 Hovda et al.
20060259026 November 16, 2006 Godara et al.
20060264957 November 23, 2006 Cragg et al.
20060264965 November 23, 2006 Shadduck et al.
20060265014 November 23, 2006 Demarais et al.
20060276749 December 7, 2006 Selmon et al.
20070027449 February 1, 2007 Godara et al.
20070055316 March 8, 2007 Godara et al.
20070118142 May 24, 2007 Krueger et al.
20070129715 June 7, 2007 Eggers et al.
20070142791 June 21, 2007 Yeung et al.
20070142842 June 21, 2007 Kreuger et al.
20070149966 June 28, 2007 Dahla et al.
20070179497 August 2, 2007 Eggers et al.
20070213584 September 13, 2007 Kim et al.
20070213735 September 13, 2007 Saadat et al.
20070260237 November 8, 2007 Sutton et al.
20080004621 January 3, 2008 Dahla et al.
20080004675 January 3, 2008 King et al.
20080009847 January 10, 2008 Ricart et al.
20080021447 January 24, 2008 Davison et al.
20080021463 January 24, 2008 Georgy
20080058707 March 6, 2008 Ashley et al.
20080065062 March 13, 2008 Leung et al.
20080091207 April 17, 2008 Truckai et al.
20080114364 May 15, 2008 Goldin et al.
20080119844 May 22, 2008 Woloszko et al.
20080119846 May 22, 2008 Rioux
20080132890 June 5, 2008 Woloszko et al.
20080161804 July 3, 2008 Rioux et al.
20080275458 November 6, 2008 Bleich et al.
20080281322 November 13, 2008 Sherman et al.
20080294166 November 27, 2008 Goldin et al.
20090030308 January 29, 2009 Bradford et al.
20090054951 February 26, 2009 Lauthardt et al.
20090069807 March 12, 2009 Eggers et al.
20090105775 April 23, 2009 Mitchell et al.
20090112278 April 30, 2009 Wingeier et al.
20090118731 May 7, 2009 Young et al.
20090131867 May 21, 2009 Liu et al.
20090131886 May 21, 2009 Liu et al.
20090149878 June 11, 2009 Truckai et al.
20090222053 September 3, 2009 Gaunt et al.
20090312764 December 17, 2009 Marino
20100010392 January 14, 2010 Skelton et al.
20100016929 January 21, 2010 Prochazka
20100023006 January 28, 2010 Ellman
20100023065 January 28, 2010 Welch et al.
20100082033 April 1, 2010 Germain
20100094269 April 15, 2010 Pellegrino et al.
20100114098 May 6, 2010 Carl
20100145424 June 10, 2010 Podhajsky et al.
20100179556 July 15, 2010 Scribner et al.
20100185082 July 22, 2010 Chandran et al.
20100185161 July 22, 2010 Pellegrino et al.
20100211076 August 19, 2010 Germain et al.
20100222777 September 2, 2010 Sutton et al.
20100261989 October 14, 2010 Boseck et al.
20100261990 October 14, 2010 Gillis et al.
20100298832 November 25, 2010 Lau et al.
20100324506 December 23, 2010 Pellegrino et al.
20110022133 January 27, 2011 Diederich et al.
20110034884 February 10, 2011 Pellegrino et al.
20110040362 February 17, 2011 Godara et al.
20110077628 March 31, 2011 Hoey et al.
20110087314 April 14, 2011 Diederich et al.
20110118735 May 19, 2011 Abou-Marie et al.
20110196361 August 11, 2011 Vilims
20110206260 August 25, 2011 Bergmans et al.
20110264098 October 27, 2011 Cobbs
20110276001 November 10, 2011 Schultz et al.
20110295261 December 1, 2011 Germain
20110319765 December 29, 2011 Gertner et al.
20120029420 February 2, 2012 Vilims
20120136346 May 31, 2012 Condie et al.
20120136348 May 31, 2012 Condie et al.
20120172858 July 5, 2012 Harrison et al.
20120172859 July 5, 2012 Condie et al.
20120196251 August 2, 2012 Taft et al.
20120197344 August 2, 2012 Taft et al.
20120203219 August 9, 2012 Evans et al.
20120226273 September 6, 2012 Nguyen et al.
20120239050 September 20, 2012 Linderman
20120265186 October 18, 2012 Burger et al.
20120330180 December 27, 2012 Pellegrino et al.
20120330300 December 27, 2012 Pellegrino et al.
20120330301 December 27, 2012 Pellegrino et al.
20130006232 January 3, 2013 Pellegrino et al.
20130006233 January 3, 2013 Pellegrino et al.
20130012933 January 10, 2013 Pellegrino et al.
20130012935 January 10, 2013 Pellegrino et al.
20130012936 January 10, 2013 Pellegrino et al.
20130012951 January 10, 2013 Linderman
20130079810 March 28, 2013 Isenberg
20130231654 September 5, 2013 Germain
20130103022 April 25, 2013 Sutton et al.
20130261507 October 3, 2013 Diederich et al.
20130324994 December 5, 2013 Pellegrino et al.
20130324996 December 5, 2013 Pellegrino et al.
20130324997 December 5, 2013 Pellegrino et al.
20130345765 December 26, 2013 Brockman et al.
20140031715 January 30, 2014 Sherar et al.
20140039500 February 6, 2014 Pellegrino et al.
20140046245 February 13, 2014 Cornacchia
20140066913 March 6, 2014 Sherman
20140088575 March 27, 2014 Loeb
20140148801 May 29, 2014 Asher et al.
20140148805 May 29, 2014 Stewart et al.
20140171942 June 19, 2014 Werneth et al.
20140221967 August 7, 2014 Childs et al.
20140236144 August 21, 2014 Krueger et al.
20140243823 August 28, 2014 Godara et al.
20140243943 August 28, 2014 Rao et al.
20140257265 September 11, 2014 Godara et al.
20140271717 September 18, 2014 Goshayeshgar et al.
20140276728 September 18, 2014 Goshayeshgar et al.
20140276744 September 18, 2014 Arthur et al.
20140288544 September 25, 2014 Diederich et al.
20140288546 September 25, 2014 Sherman et al.
20140296850 October 2, 2014 Condie et al.
20140316405 October 23, 2014 Pellegrino et al.
20140324051 October 30, 2014 Pellegrino et al.
20140336630 November 13, 2014 Woloszko et al.
20140336667 November 13, 2014 Pellegrino et al.
20140364842 December 11, 2014 Werneth et al.
20150005614 January 1, 2015 Heggeness et al.
20150005767 January 1, 2015 Werneth et al.
20150045783 February 12, 2015 Edidin
20150057658 February 26, 2015 Sutton et al.
20150065945 March 5, 2015 Zarins et al.
20150073515 March 12, 2015 Turovskiy et al.
20150141876 May 21, 2015 Diederich
20150157402 June 11, 2015 Kunis et al.
20150164546 June 18, 2015 Pellegrino et al.
20150196358 July 16, 2015 Goshayeshgar
20150216588 August 6, 2015 Deem et al.
20150231417 August 20, 2015 Metcalf et al.
20150272655 October 1, 2015 Condie et al.
20150297246 October 22, 2015 Patel et al.
20150335349 November 26, 2015 Pellegrino et al.
20150335382 November 26, 2015 Pellegrino et al.
20150342660 December 3, 2015 Nash
20150342670 December 3, 2015 Pellegrino et al.
20150359586 December 17, 2015 Heggeness
20150374432 December 31, 2015 Godara et al.
20150374992 December 31, 2015 Crosby et al.
20150374995 December 31, 2015 Foreman et al.
20160000601 January 7, 2016 Burger et al.
20160001096 January 7, 2016 Mishelevich
20160002627 January 7, 2016 Bennett et al.
20160008593 January 14, 2016 Cairns
20160008618 January 14, 2016 Omar-Pasha
20160008628 January 14, 2016 Morries et al.
20160016012 January 21, 2016 Youn et al.
20160022988 January 28, 2016 Thieme et al.
20160022994 January 28, 2016 Moffitt et al.
20160024208 January 28, 2016 MacDonald et al.
20160029930 February 4, 2016 Plumley et al.
20160030276 February 4, 2016 Spanyer
20160030408 February 4, 2016 Levin
20160030748 February 4, 2016 Edgerton et al.
20160030765 February 4, 2016 Towne et al.
20160051831 February 25, 2016 Lundmark et al.
20160059007 March 3, 2016 Koop
20160074068 March 17, 2016 Patwardhan
20160074279 March 17, 2016 Shin
20160074661 March 17, 2016 Lipani
20160081716 March 24, 2016 Boling et al.
20160095721 April 7, 2016 Schell et al.
20160106985 April 21, 2016 Zhu
20160106994 April 21, 2016 Crosby et al.
20160113704 April 28, 2016 Godara et al.
20160115173 April 28, 2016 Bois et al.
20160136310 May 19, 2016 Bradford et al.
20160144182 May 26, 2016 Bennett et al.
20160144187 May 26, 2016 Caparso et al.
20160158551 June 9, 2016 Kent et al.
20160166835 June 16, 2016 De Ridder
20160175586 June 23, 2016 Edgerton et al.
20160199097 July 14, 2016 Linderman et al.
20160213927 July 28, 2016 McGee et al.
20160220393 August 4, 2016 Slivka et al.
20160220638 August 4, 2016 Dony et al.
20160220672 August 4, 2016 Chalasani et al.
20160228131 August 11, 2016 Brockman et al.
20160228696 August 11, 2016 Imran et al.
20160235471 August 18, 2016 Godara et al.
20160235474 August 18, 2016 Prisco et al.
20160243353 August 25, 2016 Ahmed
20160246944 August 25, 2016 Jain et al.
20160250469 September 1, 2016 Kim et al.
20160250472 September 1, 2016 Carbunaru
20160262830 September 15, 2016 Werneth et al.
20160271405 September 22, 2016 Angara et al.
20160278791 September 29, 2016 Pellegrino et al.
20160278846 September 29, 2016 Harrison et al.
20160279190 September 29, 2016 Watts et al.
20160279408 September 29, 2016 Grigsby et al.
20160279411 September 29, 2016 Rooney et al.
20160279441 September 29, 2016 Imran
20160302925 October 20, 2016 Keogh et al.
20160310739 October 27, 2016 Burdick et al.
20160317053 November 3, 2016 Srivastava
20160317211 November 3, 2016 Harrison et al.
20160317621 November 3, 2016 Bright
20160324541 November 10, 2016 Pellegrino et al.
20160324677 November 10, 2016 Hyde et al.
20160325100 November 10, 2016 Lian et al.
20160339251 November 24, 2016 Kent et al.
20160354093 December 8, 2016 Pellegrino et al.
20160354233 December 8, 2016 Sansone et al.
20160367797 December 22, 2016 Eckermann
20160367823 December 22, 2016 Cowan et al.
20160375259 December 29, 2016 Davis et al.
20170001026 January 5, 2017 Schwarz et al.
20170007277 January 12, 2017 Drapeau et al.
20170014169 January 19, 2017 Dean et al.
20170027618 February 2, 2017 Lee et al.
20170028198 February 2, 2017 Degiorgio et al.
20170028201 February 2, 2017 Howard
20170035483 February 9, 2017 Crainich et al.
20170036009 February 9, 2017 Hughes et al.
20170036025 February 9, 2017 Sachs et al.
20170036033 February 9, 2017 Perryman et al.
20170042834 February 16, 2017 Westphal et al.
20170049503 February 23, 2017 Cosman
20170049507 February 23, 2017 Cosman
20170049513 February 23, 2017 Cosman
20170050017 February 23, 2017 Cosman
20170050021 February 23, 2017 Cosman
20170050024 February 23, 2017 Bhadra et al.
20170266419 September 21, 2017 Goshayeshgar
20170119461 May 4, 2017 Godara et al.
20170128080 May 11, 2017 Torrie
20170135742 May 18, 2017 Lee et al.
20170181788 June 29, 2017 Dastjerdi et al.
20170202613 July 20, 2017 Pellegrino et al.
20180021048 January 25, 2018 Pellegrino et al.
20180042656 February 15, 2018 Edidin
20180103964 April 19, 2018 Patel et al.
20180153604 June 7, 2018 Ayvazyan et al.
20180161047 June 14, 2018 Purdy et al.
20180193088 July 12, 2018 Sutton et al.
20190029698 January 31, 2019 Pellegrino et al.
20190038296 February 7, 2019 Pellegrino
20190038343 February 7, 2019 Sutton et al.
20190038344 February 7, 2019 Pellegrino
20190038345 February 7, 2019 Pellegrino
20190090933 March 28, 2019 Pellegrino et al.
20190110833 April 18, 2019 Pellegrino et al.
20190118003 April 25, 2019 Diederich et al.
20190118004 April 25, 2019 Diederich et al.
20190118005 April 25, 2019 Diederich et al.
20190282268 September 19, 2019 Pellegrino et al.
20190290296 September 26, 2019 Patel et al.
Foreign Patent Documents
43 23 585 January 1995 DE
0 040 658 December 1981 EP
0040658 December 1981 EP
0584959 March 1994 EP
0597463 May 1994 EP
0880938 December 1998 EP
1 013 228 June 2000 EP
1013228 June 2000 EP
1 059 067 December 2000 EP
1059067 December 2000 EP
1059087 December 2000 EP
2913081 January 2017 EP
6-47058 February 1994 JP
6-47058 February 1994 JP
10-290806 November 1998 JP
2001-037760 February 2001 JP
2005-169012 June 2005 JP
9636289 November 1996 WO
WO96/36289 November 1996 WO
98-27876 July 1998 WO
WO98/27876 July 1998 WO
WO98/34550 August 1998 WO
WO99/19025 April 1999 WO
WO99/44519 September 1999 WO
WO99/48621 September 1999 WO
WO00/21448 April 2000 WO
WO00/33909 June 2000 WO
WO00/49978 August 2000 WO
WO00/56237 September 2000 WO
WO00/67648 November 2000 WO
WO00/67656 November 2000 WO
WO01/01877 January 2001 WO
WO01/45579 June 2001 WO
0157655 August 2001 WO
WO01/57655 August 2001 WO
WO02/05699 January 2002 WO
WO02/05897 January 2002 WO
0228302 April 2002 WO
WO02/28302 April 2002 WO
WO2002/026319 April 2002 WO
02054941 July 2002 WO
WO02/054941 July 2002 WO
02-067797 September 2002 WO
WO02/067797 September 2002 WO
WO02/096304 December 2002 WO
WO 2009/124192 October 2009 WO
Other references
  • Bogduk, N., The anatomy of the lumbar intervertebral disc syndrome, Med J. Aust. 1976, vol. 1, No. 23, pp. 878-881.
  • A Novel Approach for Treating Chronic Lower Back Pain, Abstract for Presentation at North American Spine Society 26th Annual Meeting in Chicago, IL on Nov. 4, 2011.
  • Antonacci, M. Darryl et al.; Innervation of the Human Vertebral Body: A Histologic Study; Journal of Spinal Disorder, vol. 11, No. 6, pp. 526-531, 1998 Lippincott Williams & Wilkins, Philadelphia.
  • Arnoldi, Carl C.; Intraosseous Hypertension—A Possible Cause of Low Back Pain?; Clinical Orthopedics and Related Research, No. 115, Mar.-Apr. 1976.
  • Bailey, Jeannie F., “Innervation Patterns of PGP 9.5-Positive Nerve Fibers within the Human Lumbar Vertebra, Journal of Anatomy”, (2011) 218, pp. 263-270, San Francisco, California.
  • Bergeron et al., “Fluoroscopic-guided radiofrequency ablation of the basivertebral nerve: application and analysis with multiple imaging modalities in an ovine model,” Thermal Treatment of Tissue: Energy Delivery and Assessment III, edited by Thomas P. Ryan, Proceedings of SPIE, vol. 5698 (SPIE, Bellingham, WA, 2005) pp. 156-167.
  • Bogduk, Nikolai, et al.; Technical Limitations to the efficacy of Radiofrequency Neurotomy for Spinal Pain; Neurosurgery vol. 20, No. 4, 1987.
  • Choy, Daniel SS.J. et al.; Percutaneous Laser Disc Decompression, A New Therapeutic Modality; Spine vol. 17, No. 8, 1992.
  • Cosman, E.R. et al., Theoretical Aspects of Radiofrequency Lesions in the Dorsal Root Entry Zone. Neurosurgery, vol. 1, No. 6, 1984, pp. 945-950.
  • Deardorff, Dana L. et al.; Ultrasound applicators with internal cooling for interstitial thermal therapy; SPIE vol. 3594, 1999.
  • Dupuy, D.E. et al. Radiofrequency ablation of spinal tumors: Temperature distribution in the spinal canal AJR, vol. 175, pp. 1263-1266, Nov. 2000.
  • Dupuy, Damian E.; Radiofrequency Ablation: An Outpatient Percutaneous Treatment; Medicine and Health/Rhode Island vol. 82, No. 6, Jun. 1999.
  • Deramond, H. et al., Temperature Elevation Caused by Bone Cement Polymerization During Vertebroplasty, Bone, Aug. 1999, pp. 17S-21S, vol. 25, No. 2, Supplement.
  • Diederich, C. J. et al., “IDTT Therapy in Cadaveric Lumbar Spine: Temperature and thermal dose distributions, Thermal Treatment of Tissue: Energy Delivery and Assessment,” Thomas P. Ryan, Editor, Proceedings of SPIE vol. 4247:104-108 (2001).
  • Diederich, Chris J. et al.; Ultrasound Catheters for Circumferential Cardiac Ablation; SPIE vol. 3594 (1999).
  • Esses, Stephen I. et al.; Intraosseous Vertebral Body Pressures; Spine vol. 17 No. 6 Supplement 1992.
  • FDA Response to 510(k) Submission by Relievant Medsystems, Inc. submitted on Sep. 27, 2007 (date stamped on Oct. 5, 2007) and associated documents.
  • Fras M.D., Christian et al., “Substance P-containing Nerves within the Human Vertebral Body: An Immunohistochemical Study of the Basivertebral Nerve”, The Spine Journal 3, 2003, pp. 63-67.
  • Goldberg, S.N. et al., Tissue ablation with radiofrequency: Effect of probe size, gauge, duration, and temperature on lesion volume, Acad. Radiol., vol. 2, pp. 399-404 (1995).
  • Hanai, Kenji et al.; Simultaneous Measurement of Intraosseous and Cerebrospinal Fluid Pressures in the Lumbar Region; Spine vol. 10, No. 1, 1985.
  • Heggeness, Michael H. et al., The Trabecular Anatomy of Thoracolumbar Vertebrae: Implications for Burst Fractures, Journal of Anatomy, 1997, pp. 309-312, vol. 191, Great Britain.
  • Heggeness, Michael H. et al. Discography Causes End Plate Deflection; Spine vol. 18, No. 8, pp. 1050-1053, 1993, J.B. Lippincott Company.
  • Hoopes et al., “Radiofrequency Ablation of the Basivertebral Nerve as a Potential Treatment of Back Pain: Pathologic Assessment in an Ovine Model,” Thermal Treatment of Tissue: Energy Delivery and Assessment III, edited by Thomas P. Ryan, Proceedings of SPIE, vol. 5698 (SPIE, Bellingham, WA, 2005) pp. 168-180.
  • Houpt, Jonathan C. et al.; Experimental Study of Temperature Distributions and Thermal Transport During Radiofrequency Current Therapy of the Intervertebral Disc; Spine vol. 21, No. 15, pp. 1808-1813, 1996. Lippincott-Raven Publishers.
  • Kleinstueck, Frank S. et al.; Acute Biomechanical and Histological Effects of Intradiscal Electrothermal Therapy on Human Lumbar Discs; Spine vol. 26, No. 20, pp. 2198-2207; 2001, Lippincott Williams & Wilkins, Inc.
  • Kopecky, Kenyon K. et al. “Side-Exiting Coaxial Needle for Aspiration Biopsy”—AJR—1996; 167, pp. 661-662.
  • Lehmann, Justus F. et al.; Selective Heating Effects of Ultrasound in Human Beings; Archives of Physical Medicine & Rehabilitation Jun. 1966.
  • Letcher, Frank S. et al.; The Effect of Radiofrequency Current and Heat on Peripheral Nerve Action Potential in the Cat; U.S. Naval Hospital, Philadelphia, PA. (1968).
  • Lundskog, Jan; Heat and Bone Tissue-/an experimental investigation of the thermal properties of bone tissue and threshold levels for thermal injury; Scandinavian Journal of Plastic and Reconstructive Surgery Supplemental 9, From the Laboratory of Experimental Biology, Department of anatomy, University of Gothenburg, Gothenburg, Sweden, Goteborg 1972.
  • Martin, J.B. et al., Vertebroplasty: Clinical Experience and Follow-up Results, Bone, Aug. 1999, pp. 11S-15S, vol. 25, No. 2, Supplement.
  • Massad, Malek M.D. et al.; Endoscopic Thoracic Sympathectomy: Evaluation of Pulsatile Laser, Non-Pulsatile Laser, and Radiofrequency-Generated Thermocoagulation; Lasers in Surgery and Medicine; 1991; pp. 18-25.
  • Mehta, Mark et al.; The treatment of chronic back pain; Anaesthesia, 1979, vol. 34, pp. 768-775.
  • Nau, William H., Ultrasound interstitial thermal therapy (USITT) in the prostate; SPIE vol. 3594, Jan. 1999.
  • Rashbaum, Ralph F.; Radiofrequency Facet Denervation A Treatment alternative in Refractory Low Back Pain with or without Leg Pain; Orthopedic Clinics of North America—vol. 14, No. 3, Jul. 1983.
  • Rosenthal, D.I., Seminars in Musculoskeletal Radiology, vol. 1, No. 2., pp. 265-272 (1997).
  • Ryan et al., “Three-Dimensional Finite Element Simulations of Vertebral Body Thermal Treatment,” Thermal Treatment of Tissue: Energy Delivery and Assessment III, edited by Thomas P. Ryan, Proceedings of SPIE, vol. 5698 (SPIE, Bellingham, WA, 2005) pp. 137-155.
  • Shealy, C. Norman; Percutaneous radiofrequency denervation of spinal facets Treatment for chronic back pain and sciatica; Journal of Neurosurgery/vol. 43/Oct. 1975.
  • Sherman, Mary S.; The Nerves of Bone, The Journal of Bone and Joint Surgery, Apr. 1963, pp. 522-528, vol. 45-A, No. 3.
  • Solbiati, L. et al. Hepatic metastases: Percutaneous radio-frequency ablation with cooled-tip electrodes. Interventional Radiology, vol. 205, No. 2, pp. 367-373 (1997).
  • Stanton, Terry, “Can Nerve Ablation Reduce Chronic Back Pain?” AAOS Now Jan. 2012.
  • The AVAmax System—Cardinal Health Special Procedures, Lit. No. 25P0459-01—www.cardinal.com (copyright 2007).
  • Tillotson, L. et al. Controlled thermal injury of bone: Report of a percutaneous technique using radiofrequency electrode and generator. Investigative Radiology, Nov. 1989, pp. 888-892.
  • Troussier, B. et al.; Percutaneous Intradiscal Radio-Frequency Thermocoagulation A Cadaveric Study; Spine vol. 20, No. 15, pp. 1713-1718, 1995, Lippincott-Raven Publishers.
  • Ullrich, Jr., Peter F., “Lumbar Spinal Fusion Surgery” Jan. 9, 2013, Spine-Health (available via wayback machine Internet archive at http://web.archive.org/web/20130109095419/http://www/spine-health.com/treatment/spinal-fusion/lumbar-spinal-fusion-surgery).
  • Osteocool Pain Management Brochure, Baylis Medical, copyright 2011.
  • Gehl, J., “Electroporation: theory and methods, perspectives for drug delivery, gene therapy, and research”, Acta Physiol. Scand., vol. 177, pp. 437-447 (2003).
  • Modic MT et al.; “Degenerative disk disease: assessment of changes in vertebral body marrow with MR imaging”, Radiology, vol. 166, pp. 193-199 (1988).
  • Weishaupt, D et al,; “Painful Lumbar Disk Derangement: Relevance of Endplate Abnormalities at MR Imaging”, Radiology, vol. 218(2), pp. 420-427 (2001).
  • E.R. Cosman et al. Theoretical aspects of radiofrequency lesions in the dorsal root entry zone. Neurosurgery, vol. 15, No. 6, pp. 945-950 (1984).
Patent History
Patent number: RE48460
Type: Grant
Filed: Mar 24, 2017
Date of Patent: Mar 9, 2021
Assignee: Relievant Medsystems, Inc. (Minneapolis, MN)
Inventors: Richard Pellegrino (Leesburg, VA), Paula Papineau (West Bridgewater, MA), John S. Crombie (East Hanover, NJ), Samit Patel (Palo Alto, CA), Thomas Ryan (Asheville, NC)
Primary Examiner: Beverly M Flanagan
Application Number: 15/469,315
Classifications
Current U.S. Class: Applicators (606/41)
International Classification: A61B 18/14 (20060101); A61B 18/00 (20060101);